CA2455453C - Taxol enhancer compounds - Google Patents
Taxol enhancer compounds Download PDFInfo
- Publication number
- CA2455453C CA2455453C CA2455453A CA2455453A CA2455453C CA 2455453 C CA2455453 C CA 2455453C CA 2455453 A CA2455453 A CA 2455453A CA 2455453 A CA2455453 A CA 2455453A CA 2455453 C CA2455453 C CA 2455453C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- group
- substituted
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D8/00—Hair-holding devices; Accessories therefor
- A45D8/004—Hair-holding devices; Accessories therefor with decorative arrangements or form
- A45D8/006—Interchangeable ornaments attached to hair holding devices
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Disclosed is a compound represented by the Structural Formula (I); Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z
groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or -C(R7R8)-. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is =O or =S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.
groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or -C(R7R8)-. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is =O or =S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.
Description
CIO 03, 046430 PCTIUS02121717 I
TAXOL ENHANCER. COMPOUNDS
BACKGROUND OF THE INVENTION
Many new drugs are now available to be used by oncologists in treating patients with cancer. Often, tumors are more responsive to treatment when anti-cancer drugs are administered in combination to the patient than when the same drugs are administered individually and sequentially. One advantage of this approach is that the anti-cancer agents often act synergistically because the tumors ce.i S are attacked simultaneously with agents having multiple modes of action. Thus, it is often possible to achieve more rapid reductions in tumor size by administering these drags in combination. Another advantage of combination chemotherapy is that tumors are more likely to be eradicated completely and are less likely to develop 2() resistance to the anti-cancer drugs being used to treat the patient.
One serious limitation. of combination chemotherapy is that anti-cancer a,enrs generally have severe side effects, even when administered individually. For example, the Nell known anti-cancer agent taxol causes neutroperia, neuropathy, 1'_ ucositis, anemia, thrombocytopenia, bradycardia, diarrhea and nausea.
nfortunately, the toxicity of anti-cancer agents is generally additive when the drugs arc administered in combination. As result, certain types of anti-cancer drugs are Centrally not combined. The combined toxic side-effects of those anti-cancer drugs that are administered simultaneously can place severe limitations on the quantities that can be used in combination. Often, it is not possible to use enough of the c orrbination therapy to achieve the desired synergistic effects. Therefore, there is an urgent need for agents which can enhance the desirable tumor attacking properties of anti-cancer agents without further increasing their undesirable side-effects.
SUMMARY OF THE INVENTION
It has now been found that certain bis[thio-hydrazide amide] compounds significantly enhance the anti-cancer activity of taxol. For example, Compound (1) was used in combination with taxol (Paclitaxel) to treat tumors induced in nude mice from the human breast tumor cell line MDA-435. The tumor volume was about five fold less after 24 days of treatment in mice which had been administered 5 mg/kg of taxol and 25 mg/kg of Compound (1) than in mice which had only been administered 5 mg/kg of taxol or in mice which had only been administered 50 mg/kg of Compound (1) (Example 13). These results are shown graphically in Figure 1. The structure of Compound (1) is shown below:
N NH H
f I YU
S S
Compound (1) It has also been found that these bis[thio-hydrazide amide] compounds have minimal toxic side effects. For example, the mice treated with taxol and Compound (1) showed little if any weight loss over the treatment period (see Figure 2).
Based on these results, novel compounds which enhance the anti-cancer activity of taxol, pharmaceutical compositions comprising these compounds and methods of treating a subject with cancer are disclosed herein.
One embodiment of the present invention is a compound represented by the Structural Formula (I):
TAXOL ENHANCER. COMPOUNDS
BACKGROUND OF THE INVENTION
Many new drugs are now available to be used by oncologists in treating patients with cancer. Often, tumors are more responsive to treatment when anti-cancer drugs are administered in combination to the patient than when the same drugs are administered individually and sequentially. One advantage of this approach is that the anti-cancer agents often act synergistically because the tumors ce.i S are attacked simultaneously with agents having multiple modes of action. Thus, it is often possible to achieve more rapid reductions in tumor size by administering these drags in combination. Another advantage of combination chemotherapy is that tumors are more likely to be eradicated completely and are less likely to develop 2() resistance to the anti-cancer drugs being used to treat the patient.
One serious limitation. of combination chemotherapy is that anti-cancer a,enrs generally have severe side effects, even when administered individually. For example, the Nell known anti-cancer agent taxol causes neutroperia, neuropathy, 1'_ ucositis, anemia, thrombocytopenia, bradycardia, diarrhea and nausea.
nfortunately, the toxicity of anti-cancer agents is generally additive when the drugs arc administered in combination. As result, certain types of anti-cancer drugs are Centrally not combined. The combined toxic side-effects of those anti-cancer drugs that are administered simultaneously can place severe limitations on the quantities that can be used in combination. Often, it is not possible to use enough of the c orrbination therapy to achieve the desired synergistic effects. Therefore, there is an urgent need for agents which can enhance the desirable tumor attacking properties of anti-cancer agents without further increasing their undesirable side-effects.
SUMMARY OF THE INVENTION
It has now been found that certain bis[thio-hydrazide amide] compounds significantly enhance the anti-cancer activity of taxol. For example, Compound (1) was used in combination with taxol (Paclitaxel) to treat tumors induced in nude mice from the human breast tumor cell line MDA-435. The tumor volume was about five fold less after 24 days of treatment in mice which had been administered 5 mg/kg of taxol and 25 mg/kg of Compound (1) than in mice which had only been administered 5 mg/kg of taxol or in mice which had only been administered 50 mg/kg of Compound (1) (Example 13). These results are shown graphically in Figure 1. The structure of Compound (1) is shown below:
N NH H
f I YU
S S
Compound (1) It has also been found that these bis[thio-hydrazide amide] compounds have minimal toxic side effects. For example, the mice treated with taxol and Compound (1) showed little if any weight loss over the treatment period (see Figure 2).
Based on these results, novel compounds which enhance the anti-cancer activity of taxol, pharmaceutical compositions comprising these compounds and methods of treating a subject with cancer are disclosed herein.
One embodiment of the present invention is a compound represented by the Structural Formula (I):
3 z z Rj N \ "'k y / N R2 N Y N
I S
(I).
Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z
groups to which it is bonded, is a substituted or unsubstituted aromatic group.
Preferably, Y is a covalent bond or -C(R7R8)-.
Rl and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
Z is =0 or =S.
In one aspect, Rl and R2 in the compound represented by Structural Formula (I) are not both phenyl when Y is -C(R7R8)-, R3 and R4 are both phenyl and R5-are all -H.
Another embodiment of the present invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I). Preferably, the pharmaceutical composition comprises an effective concentration of the compound.
Yet another embodiment of the present invention is a method of treating a subject with cancer. The method comprises administering to the subject an effective amount of taxol or a taxol analog and an effective amount of a compound represented by Structural Formula (1).
The disclosed compounds increase the anti-cancer activity of taxol and taxol analogs. In addition, these compounds have minimal toxic side-effects.
Consequently, it is possible to increase the effectiveness of taxol and analogs thereof when used in combination with the disclosed compounds, even when approaching the highest tolerated doses of taxol. Thus, it is expected that combination therapy with the compounds of the present invention will provide improved clinical outcomes for patients with cancers that are being treated with taxol. By co-administering the disclosed compounds with taxol, it is also possible to achieve the same therapeutic effectiveness previously achieved with higher doses of taxol, thereby reducing the side-effects and improving the quality of life for the patient.
I S
(I).
Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z
groups to which it is bonded, is a substituted or unsubstituted aromatic group.
Preferably, Y is a covalent bond or -C(R7R8)-.
Rl and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
Z is =0 or =S.
In one aspect, Rl and R2 in the compound represented by Structural Formula (I) are not both phenyl when Y is -C(R7R8)-, R3 and R4 are both phenyl and R5-are all -H.
Another embodiment of the present invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I). Preferably, the pharmaceutical composition comprises an effective concentration of the compound.
Yet another embodiment of the present invention is a method of treating a subject with cancer. The method comprises administering to the subject an effective amount of taxol or a taxol analog and an effective amount of a compound represented by Structural Formula (1).
The disclosed compounds increase the anti-cancer activity of taxol and taxol analogs. In addition, these compounds have minimal toxic side-effects.
Consequently, it is possible to increase the effectiveness of taxol and analogs thereof when used in combination with the disclosed compounds, even when approaching the highest tolerated doses of taxol. Thus, it is expected that combination therapy with the compounds of the present invention will provide improved clinical outcomes for patients with cancers that are being treated with taxol. By co-administering the disclosed compounds with taxol, it is also possible to achieve the same therapeutic effectiveness previously achieved with higher doses of taxol, thereby reducing the side-effects and improving the quality of life for the patient.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.
Figure 1 is a graph showing the average tumor volume in milliliters over time (in days) in nude mice treated with vehicle; Compound (1) (50 mg/kg);
Paclitaxel (5 mg/kg); Compound (1) (25 mg/kg) and Paclitaxel (5 mg/kg); or Compound (1) (50 mg/kg) and Paclitaxel (5 mg/kg). The tumors were generated from the human breast tumor cell line MDA-43 5.
Figure 2 is a graph showing the percent weight change over time in nude mice treated with vehicle; Compound (1) (50 mg/kg); Paclitaxel (5 mg/kg);
Compound (1) (25 mg/kg) and Paclitaxel (5 mg/kg); or Compound (1) (50 mg/kg) and Paclitaxel (5 mg/kg). The mice were being treated for tumors generated from the human breast tumor cell line MDA-43 5.
Figure 3 is the structure of taxol (Paclitaxel) Figure 4 is the structure of taxotere (Docetaxel) Figures 5-25 are each the structure of a taxol analog.
Figure 26 is the structure of a polymer comprising a taxol analog group pendent from the polymer backbone. The polymer is a terpolymer of the three monomer units shown.
DETAILED DESCRIPTION OF THE INVENTION
In a first preferred embodiment, Y in Structural Formula (1), taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted arylene group and the compound is represented by Structural Formula (II):
I I
R1 Y N\ NAr\`NN R2 S R5 is S
(II).
RI-R6 in Structural Formula (II) are as described in Structural Formula (I).
Ar is a substituted or unsubstituted arylene group. Preferably, Ar is a nitrogen-containing heteroarylene group. Examples are shown below:
N N/\N
{ A I A' A
~2 L N/
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.
Figure 1 is a graph showing the average tumor volume in milliliters over time (in days) in nude mice treated with vehicle; Compound (1) (50 mg/kg);
Paclitaxel (5 mg/kg); Compound (1) (25 mg/kg) and Paclitaxel (5 mg/kg); or Compound (1) (50 mg/kg) and Paclitaxel (5 mg/kg). The tumors were generated from the human breast tumor cell line MDA-43 5.
Figure 2 is a graph showing the percent weight change over time in nude mice treated with vehicle; Compound (1) (50 mg/kg); Paclitaxel (5 mg/kg);
Compound (1) (25 mg/kg) and Paclitaxel (5 mg/kg); or Compound (1) (50 mg/kg) and Paclitaxel (5 mg/kg). The mice were being treated for tumors generated from the human breast tumor cell line MDA-43 5.
Figure 3 is the structure of taxol (Paclitaxel) Figure 4 is the structure of taxotere (Docetaxel) Figures 5-25 are each the structure of a taxol analog.
Figure 26 is the structure of a polymer comprising a taxol analog group pendent from the polymer backbone. The polymer is a terpolymer of the three monomer units shown.
DETAILED DESCRIPTION OF THE INVENTION
In a first preferred embodiment, Y in Structural Formula (1), taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted arylene group and the compound is represented by Structural Formula (II):
I I
R1 Y N\ NAr\`NN R2 S R5 is S
(II).
RI-R6 in Structural Formula (II) are as described in Structural Formula (I).
Ar is a substituted or unsubstituted arylene group. Preferably, Ar is a nitrogen-containing heteroarylene group. Examples are shown below:
N N/\N
{ A I A' A
~2 L N/
5 Ring A is substituted or unsubstituted.
In a second preferred embodiment, Y in Structural Formula (I) is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R7 and R8 are as described for Structural Formula (1). Preferably, Y is a covalent bond, -C(R7R8)-, -(CH2CH2)-, trans-(CH=CH)-, cis-(CH=CH)-, -(CC)- or a 1,4-phenylene group. Even more preferably, Y is a covalent bond or -C(R7R8)-.
In a third preferred embodiment, Y in Structural Formula (I) is a covalent bond or -C(R7R8)- and the compound of the present invention is represented by Structural Formula (III):
Rj N \
',k - / N 'R2 N Y' N
f I 6 S
(i) RI-R8 are as described for Structural Formula (I). Y' is a covalent bond or -C(R7R8)-. Preferably, R7 and R8 are both methyl; R7 and R8, taken together, are propylene or butylene; or R7 is -H and R8 is lower alkyl (preferably methyl), thienyl, phenyl, benzyl, or amino.
In a more preferred embodiment, R5-R8 in Structural Formula (III) are -H
and the compound is represented by Structural Formula (IV):
f3 0 0 14 Rq N "'K /N Y R2 N Y" N
H H
S S
(N).
In a second preferred embodiment, Y in Structural Formula (I) is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R7 and R8 are as described for Structural Formula (1). Preferably, Y is a covalent bond, -C(R7R8)-, -(CH2CH2)-, trans-(CH=CH)-, cis-(CH=CH)-, -(CC)- or a 1,4-phenylene group. Even more preferably, Y is a covalent bond or -C(R7R8)-.
In a third preferred embodiment, Y in Structural Formula (I) is a covalent bond or -C(R7R8)- and the compound of the present invention is represented by Structural Formula (III):
Rj N \
',k - / N 'R2 N Y' N
f I 6 S
(i) RI-R8 are as described for Structural Formula (I). Y' is a covalent bond or -C(R7R8)-. Preferably, R7 and R8 are both methyl; R7 and R8, taken together, are propylene or butylene; or R7 is -H and R8 is lower alkyl (preferably methyl), thienyl, phenyl, benzyl, or amino.
In a more preferred embodiment, R5-R8 in Structural Formula (III) are -H
and the compound is represented by Structural Formula (IV):
f3 0 0 14 Rq N "'K /N Y R2 N Y" N
H H
S S
(N).
R1-R4 in Structural Formula (IV) are as described in Structural Formula (I).
Y" is a covalent bond or -CH2-.
In a first example of a compound represented by Structural Formula (IV), R3 and R4 are both a substituted or unsubstituted aliphatic group, preferably both a substituted or unsubstituted lower alkyl group and more preferably both a methyl group or ethyl. When R3 and R4 in Structural Formula (IV) are both a substituted or unsubstituted aliphatic group, then RI and R2 are preferably both a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted phenyl group, or a phenyl group with at least one substituent other than an aliphatic group).
In a second example of a compound represented by Structural Formula (IV), R3 and R4 are both a substituted or unsubstituted heteroaryl group. When R3 and R4 in Structural Formula (IV) are both a substituted or unsubstituted heteroaryl group, then R1 and R2 are preferably both: 1) a substituted or unsubstituted phenyl group; or 2) a substituted or unsubstituted heteroaryl group.
In a third example of a compound represented by Structural Formula (IV), R3 and R4 are both a substituted or unsubstituted phenyl group (e.g., a phenyl group substituted with at least one group other than an aliphatic group). When R3 and R4 in Structural Formula (IV) are both a substituted or unsubstituted phenyl group, then R1 and R2 are preferably both: 1) a substituted or unsubstituted phenyl group;
or 2) a substituted or unsubstituted heteroaryl group.
In a fourth example of a compound represented by Structural Formula (IV), R1 and R2 are both a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted phenyl group or a phenyl group substituted with at least one group other than an aliphatic group). More preferably, R3 and R4 are both methyl and the remainder of the variables are as described above.
In a fourth preferred embodiment, the compound of the present invention is represented by Structural Formula (III), wherein at least one of R1-R4 is a heteroaryl group, a substituted heteroaryl group, or a phenyl group substituted with at least one group other than an aliphatic group. Preferably, R5-R8 are all -H.
The following are specific examples of compounds represented by Structural Formula (IV): R1 and R2 are both phenyl, and R3 and R4 are both o-CH3-phenyl;
and R2 are both o-CH3C(O)O-phenyl, and R3 and R4 are phenyl; RI and R2 are both phenyl, and R3 and R4 are both methyl; R1 and R2 are both phenyl, and R3 and R4 are both ethyl; Rl and R2 are both phenyl, and R3 and R4 are both n-propyl; R1 and R2 are both p-cyanophenyl, and R3 and R4 are both methyl; R1 and R2 are both p-nitro phenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,5-dimethoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both phenyl, and R3 and R4 are both n-butyl; R1 and R2 are both p-chlorophenyl, and R3 and R4 are both methyl;
R1 and R2 are both 3-nitrophenyl, and R3 and R4 are both methyl; R1 and R2 are both 3-cyanophenyl, and R3 and R4 are both methyl; R, and R2 are both 3-fluorophenyl, and R3 and R4 are both methyl; R1 and R2 are both 2-furanyl, and R3 and R4 are both phenyl;
R1 and R2 are both 2-methoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both 3-methoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,3-dimethoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both 2-methoxy-5-chlorophenyl, and R3 and R4 are both ethyl; R1 and R2 are both 2,5-difluorophenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,5-dichorophenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,5-dimethylphenyl, and-R3 and R4 are both methyl;
R1 and R2 are both 2-methoxy-5-chlorophenyl, and R3 and R4 are both methyl;
R, and R2 are both 3,6-dimethoxyphenyl, and R3 and R4 are both methyl; R1 and are both phenyl, and R3 and R4 are both 2-ethylphenyl; R1 and R2 are both 2-methyl-5-pyridyl, and R3 and R4 are both methyl; or R1 is phenyl; R2 is 2,5-dimethoxyphenyl, and R3 and R4 are both methyl.
In a fifth preferred embodiment, Y in Structural Formula (I) is -C(R7R8)- and R5 and R6 are both -H. When Y is a covalent bond or -CR7R8- and R5 and R6 are both -H, the compound of the present invention is represented by Structural Formula (V):
Rj N "-k /N R2 N Y' N
H H
S S
M.
R,-R4, R7 and R8 are as described for Structural Formula (I) and Y' is a covalent bond or -CR7R8-. R7 and R8 are the same or different. Preferably, R7 and R5 are both methyl; R7 and R8, taken together, are propylene or butylene; or R7 is -H and R8 is lower alkyl (preferably methyl), thienyl, phenyl or benzyl.
In one example of a compound represented by Structural Formula (V), R1 and R2 are both aryl or substituted aryl groups and R3 and R4 are both a lower alkyl group or a substituted lower alkyl group; preferably, R1 and R2 are both aryl or substituted aryl groups, R3 and R4 are both methyl or ethyl, R7 is -H and R8 is -H or methyl.
In another example of a compound represented by Structural Formula (V), R1 and R2 are both phenyl or substituted phenyl and R3 and R4 are both methyl, ethyl, phenyl, or thienyl.
When R1 and R2 are both phenyl or substituted phenyl and R3 and R4 are both methyl, ethyl, phenyl, or thienyl, then preferably R7 and R8, taken together, are propylene or butylenes. In yet another example of a compound represented by Structural Formula (V), Y' is a covalent bond or -CR7R8-; R1 and R2 are both a substituted or unsubstituted aryl group; R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
The following are specific examples of compounds represented by Structural Formula (V): R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is ethyl; R1 and R2 are both phenyl; R3 and R4 are both phenyl, and R7 and R8 are both methyl; R1 and R2 are both 2-thienyl; R3 and R4 are both phenyl, and R7 and R8 are both methyl; R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl;
R7 is -H, and R8 is methyl; RI and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is benzyl; R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is ethyl; R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 is -H, and R8 is n-butyl; RI and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; RI and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is iso-propyl; R1 and R2 are both 3-nitrophenyl; R3 and R4 are both methyl;
R7 is -H, and R8 is methyl; RI and R2 are both 4-chlorophenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is 3-thienyl; R1 and R2 are both phenyl; R3 and R4 are both methyl, and R7 and R8, taken together, are propylene; R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; RI and are both 2-chloro-5-methoxy phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both 2,5-dichlorophenyl; R3 and R4 are both methyl;
R7 is -H, and R8 is methyl; R1 and R2 are both 2,6-dimethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; RI and R2 are both 2,5-dimethylphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both ethyl; R7 is -H, and R8 is methyl, and R1 and R2 are both 2,5-diethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl.
In a sixth preferred embodiment, Y in Structural Formula (1) is a covalent bond or -CH2-. When Y is a covalent bond or -CH2-, the compound of the present invention is represented by Structural Formula (VI):
Y" is a covalent bond or -CH2-.
In a first example of a compound represented by Structural Formula (IV), R3 and R4 are both a substituted or unsubstituted aliphatic group, preferably both a substituted or unsubstituted lower alkyl group and more preferably both a methyl group or ethyl. When R3 and R4 in Structural Formula (IV) are both a substituted or unsubstituted aliphatic group, then RI and R2 are preferably both a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted phenyl group, or a phenyl group with at least one substituent other than an aliphatic group).
In a second example of a compound represented by Structural Formula (IV), R3 and R4 are both a substituted or unsubstituted heteroaryl group. When R3 and R4 in Structural Formula (IV) are both a substituted or unsubstituted heteroaryl group, then R1 and R2 are preferably both: 1) a substituted or unsubstituted phenyl group; or 2) a substituted or unsubstituted heteroaryl group.
In a third example of a compound represented by Structural Formula (IV), R3 and R4 are both a substituted or unsubstituted phenyl group (e.g., a phenyl group substituted with at least one group other than an aliphatic group). When R3 and R4 in Structural Formula (IV) are both a substituted or unsubstituted phenyl group, then R1 and R2 are preferably both: 1) a substituted or unsubstituted phenyl group;
or 2) a substituted or unsubstituted heteroaryl group.
In a fourth example of a compound represented by Structural Formula (IV), R1 and R2 are both a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted phenyl group or a phenyl group substituted with at least one group other than an aliphatic group). More preferably, R3 and R4 are both methyl and the remainder of the variables are as described above.
In a fourth preferred embodiment, the compound of the present invention is represented by Structural Formula (III), wherein at least one of R1-R4 is a heteroaryl group, a substituted heteroaryl group, or a phenyl group substituted with at least one group other than an aliphatic group. Preferably, R5-R8 are all -H.
The following are specific examples of compounds represented by Structural Formula (IV): R1 and R2 are both phenyl, and R3 and R4 are both o-CH3-phenyl;
and R2 are both o-CH3C(O)O-phenyl, and R3 and R4 are phenyl; RI and R2 are both phenyl, and R3 and R4 are both methyl; R1 and R2 are both phenyl, and R3 and R4 are both ethyl; Rl and R2 are both phenyl, and R3 and R4 are both n-propyl; R1 and R2 are both p-cyanophenyl, and R3 and R4 are both methyl; R1 and R2 are both p-nitro phenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,5-dimethoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both phenyl, and R3 and R4 are both n-butyl; R1 and R2 are both p-chlorophenyl, and R3 and R4 are both methyl;
R1 and R2 are both 3-nitrophenyl, and R3 and R4 are both methyl; R1 and R2 are both 3-cyanophenyl, and R3 and R4 are both methyl; R, and R2 are both 3-fluorophenyl, and R3 and R4 are both methyl; R1 and R2 are both 2-furanyl, and R3 and R4 are both phenyl;
R1 and R2 are both 2-methoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both 3-methoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,3-dimethoxyphenyl, and R3 and R4 are both methyl; R1 and R2 are both 2-methoxy-5-chlorophenyl, and R3 and R4 are both ethyl; R1 and R2 are both 2,5-difluorophenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,5-dichorophenyl, and R3 and R4 are both methyl; R1 and R2 are both 2,5-dimethylphenyl, and-R3 and R4 are both methyl;
R1 and R2 are both 2-methoxy-5-chlorophenyl, and R3 and R4 are both methyl;
R, and R2 are both 3,6-dimethoxyphenyl, and R3 and R4 are both methyl; R1 and are both phenyl, and R3 and R4 are both 2-ethylphenyl; R1 and R2 are both 2-methyl-5-pyridyl, and R3 and R4 are both methyl; or R1 is phenyl; R2 is 2,5-dimethoxyphenyl, and R3 and R4 are both methyl.
In a fifth preferred embodiment, Y in Structural Formula (I) is -C(R7R8)- and R5 and R6 are both -H. When Y is a covalent bond or -CR7R8- and R5 and R6 are both -H, the compound of the present invention is represented by Structural Formula (V):
Rj N "-k /N R2 N Y' N
H H
S S
M.
R,-R4, R7 and R8 are as described for Structural Formula (I) and Y' is a covalent bond or -CR7R8-. R7 and R8 are the same or different. Preferably, R7 and R5 are both methyl; R7 and R8, taken together, are propylene or butylene; or R7 is -H and R8 is lower alkyl (preferably methyl), thienyl, phenyl or benzyl.
In one example of a compound represented by Structural Formula (V), R1 and R2 are both aryl or substituted aryl groups and R3 and R4 are both a lower alkyl group or a substituted lower alkyl group; preferably, R1 and R2 are both aryl or substituted aryl groups, R3 and R4 are both methyl or ethyl, R7 is -H and R8 is -H or methyl.
In another example of a compound represented by Structural Formula (V), R1 and R2 are both phenyl or substituted phenyl and R3 and R4 are both methyl, ethyl, phenyl, or thienyl.
When R1 and R2 are both phenyl or substituted phenyl and R3 and R4 are both methyl, ethyl, phenyl, or thienyl, then preferably R7 and R8, taken together, are propylene or butylenes. In yet another example of a compound represented by Structural Formula (V), Y' is a covalent bond or -CR7R8-; R1 and R2 are both a substituted or unsubstituted aryl group; R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
The following are specific examples of compounds represented by Structural Formula (V): R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is ethyl; R1 and R2 are both phenyl; R3 and R4 are both phenyl, and R7 and R8 are both methyl; R1 and R2 are both 2-thienyl; R3 and R4 are both phenyl, and R7 and R8 are both methyl; R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl;
R7 is -H, and R8 is methyl; RI and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is benzyl; R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is ethyl; R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 is -H, and R8 is n-butyl; RI and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; RI and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is iso-propyl; R1 and R2 are both 3-nitrophenyl; R3 and R4 are both methyl;
R7 is -H, and R8 is methyl; RI and R2 are both 4-chlorophenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is 3-thienyl; R1 and R2 are both phenyl; R3 and R4 are both methyl, and R7 and R8, taken together, are propylene; R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; RI and are both 2-chloro-5-methoxy phenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both 2,5-dichlorophenyl; R3 and R4 are both methyl;
R7 is -H, and R8 is methyl; R1 and R2 are both 2,6-dimethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; RI and R2 are both 2,5-dimethylphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl; R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both ethyl; R7 is -H, and R8 is methyl, and R1 and R2 are both 2,5-diethoxyphenyl; R3 and R4 are both methyl; R7 is -H, and R8 is methyl.
In a sixth preferred embodiment, Y in Structural Formula (1) is a covalent bond or -CH2-. When Y is a covalent bond or -CH2-, the compound of the present invention is represented by Structural Formula (VI):
R1 N \ / N R2 N Y" N
I I
M.
R1-R6 in Structural Formula (VI) are as described for Structural Formula (1).
R5 and R6 are the same or different. Y" is a covalent bond or -CH2-.
In one example of a compound represented by Structural Formula (VI), R5 and R6 are both a lower alkyl group (preferably methyl) or a phenyl group.
When R5 and R6 are both a lower alkyl group or a phenyl group, then Rl and R2 are preferably both phenyl or substituted phenyl and R3 and R4 are preferably both a lower alkyl group.
The following are more specific examples of compounds of the present invention: Rl and R2 are both phenyl, R3 and R4 are both phenyl, R5 and R6 are both methyl, and R7 and R8 are both -H; RI and R2 are both phenyl, R3 and R4 are both phenyl, R5 and R6 are both n-hexyl, and R7 and R8 are both -H; R1 and R2 are both phenyl, R3 and R4 are both methyl, R5 and R6 are both methyl, and R7 and R8 are both -H; R1 and R2 are both phenyl, R3 and R4 are both methyl, R5 and R6 are both methyl, and R7 is -H and R8 is methyl; RI and R2 are both phenyl, R3 and R4 are both -H, R5 and R6 are both phenyl, R7 is -H, and R8 is methyl; Rl and R2 are both chlorophenyl, R3 and R4 are both methyl, R5 and R6 are both methyl, and R7 and are both -H.
In Structural Formulas (I)-(VI), Rl and R2 are the same or different; and/or R3 and R4 are the same or different. Preferably, R1 and R2 are the same, and R3 and R4 are the same.
A "straight chained hydrocarbyl group" is an alkylene group, i.e., -(CH2)X , with one or more (preferably one) methylene groups optionally replaced with a linkage group. x is a positive integer (e.g., between 1 and about 10), preferably between 1 and about 6 and more preferably 1 or 2. A "linkage group" refers to a functional group which replaces a methylene in a straight chained hydrocarbyl.
Examples of suitable linkage groups include a ketone (-C(O)-), alkene, alkyne, phenylene, ether (-0-), thioether (-S-), or amine [-N(Ra)]-, wherein Ra is defined below. A preferred linkage group is -C(R7R8)-, wherein R7 and R8 are defined above.
Suitable substitutents for an alkylene group and a hydrocarbaryl group are those which do not substantially interfere with the reactions described herein. R7 and R8 are preferred substituents for an alkylene or hydrocabbyl group.
An aliphatic group is a straight chained, branched or cyclic non-aromatic hydrocarbon which is completely saturated or which contains one or more units of 5 unsaturation. Typically, a straight chained or branched aliphatic group has from 1 to about 20 carbon atoms, preferably from 1 to about 10, and a cyclic aliphatic group has from 3 to about 10 carbon atoms, preferably from 3 to about 8. An aliphatic group is preferably a straight chained or branched alkyl group, e.g, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tent-butyl, pentyl, hexyl, pentyl or octyl, or a 10 cycloalkyl group with 3 to about 8 carbon atoms. A C1-C20 straight chained or branched alkyl group or a C3-C8 cyclic alkyl group is also referred to as a "lower alkyl" group.
Aromatic groups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, thienyl, furanyl, pyridyl, pyrimidy, pyranyl, pyrazolyl, pyrroyl, pyrazinyl, thiazole, oxazolyl, and tetrazole.
Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazole, benzooxazole, benzimidazole, quinolinyl, isoquinolinyl and isoindolyl.
The term "arylene" refers to an aryl group which is connected to the remainder of the molecule by two other bonds. By way of example, the structure of a 1,4-phenylene group is shown below:
Substituents for an arylene group are as described below for an aryl group.
Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered. Examples include tetrahydrofuranyl, tetrahyrothiophenyl, morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, and thiazolidinyl.
The terms "lower alkoxy", "lower acyl", "(lower alkoxy)methyl" and "(lower alkyl)thiomethyl" mean to -O-(lower alkyl), -C(O)-(lower alkyl), -CH2-O-(lower alkyl) and -CH2-S-(lower alkyl), respectively. The terms "substituted lower alkoxy" and "substituted lower acyl" mean -O-(substituted lower alkyl) and -C(O)-(substituted lower alkyl), respectively.
Suitable substituents on an aliphatic group, non-aromatic heterocyclic group.
benzylic or aryl group (carbocyclic and heteroaryl) are those which do not substantially interfere with the ability of the disclosed compounds to enhance the anti-cancer activity of taxol and analogs thereof. A substituent substantially interferes with the ability of a disclosed compound to enhance anti-cancer activity when the enhancement is reduced by more than about 50% in a compound with the substituent compared with a compound without. the substituent. Examples of suitable substituents include -OH, halogen (-Br, -Cl, -I and -F), -ORa, -O-CORa, -CORa, -CN, -NO2, -COOH, -SO3H, -NH2, -NHRa, -N(RaRb), -COORa, -CHO, -CONH2, -CONHRa, -CON(RaRb), -NHCORa, -NRCORa, -NHCONH2, -NHCONRaH, -NHCON(RaRb), -NRcCONH2, -NRcCONRaH, -NR CON(RaR), -C(=NH)-NH2, -C(=NH)-NHRa, -C(=NH)-N(RaRb), -C(=NR )-NH2, -C(=NR )-NHRa, -C(=NR )-N(RaRb), -NH-C(=NH)-NH2, -NH-C(=NH)-NHRa, -NH-C(=NH)-N(RaR), -NH-C(=NRc)-NH., -NH-C(=NRc)-NHRa, -NH-C(=NR )-N(RaRb), -NRdH-C(=NH)-NH2, -NRd-C(=NH)-NHRa, -NRd-C(=NH)-N(RaRb), -NRd-C(=NR )-NH2, -NRd-C(=NRc)-NHRa, -NRd-C(=NR )-N(RaRb), -NHNH2, -NHNHRa, -NHRaRb, -S02NH2a -S02NHRa, -SO2NRaRb, -CH=CHRa, -CH=CRaRb, -CR =CRaRb,-CR =CHRa, -CRc=CRaRb, -CCRa, -SH, -SOkR" (k is 0, 1 or 2) and -NH-C(=NH)-NH2. Ra-Rd are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group, preferably an alkyl, benzylic or aryl group. In addition, -NRaRd , taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group. A non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent. A
substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent.
Also included in the present invention are pharmaceutically acceptable salts of the compounds described herein. The compound of the present invention which possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
Examples of such salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-l -sulfonate, naphthalene-2-sulfonate, mandelate, and the like.
Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.
Taxol, also referred to as "Paclitaxel", is a well-known anti-cancer drug which acts by inhibiting microtubule formation. Many analogs of taxol are known, including taxotere, the structure of which is shown in Figure 4. Taxotere is also referred to as ""Docetaxol". The structure of other taxol analogs are shown in Figures 5-25. These compounds have the basic taxane skeleton as a common structure feature and have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules. Thus, it is apparent from Figures that a wide variety of substituents can decorate the taxane skeleton without adversely affecting biological activity. It is also apparent that zero, one or both of the cyclohexane rings of a taxol analog can have a double bond at the indicated positions. For clarity purposes, the basic taxane skelton is shown below in Structural Formula (VII):
I I
M.
R1-R6 in Structural Formula (VI) are as described for Structural Formula (1).
R5 and R6 are the same or different. Y" is a covalent bond or -CH2-.
In one example of a compound represented by Structural Formula (VI), R5 and R6 are both a lower alkyl group (preferably methyl) or a phenyl group.
When R5 and R6 are both a lower alkyl group or a phenyl group, then Rl and R2 are preferably both phenyl or substituted phenyl and R3 and R4 are preferably both a lower alkyl group.
The following are more specific examples of compounds of the present invention: Rl and R2 are both phenyl, R3 and R4 are both phenyl, R5 and R6 are both methyl, and R7 and R8 are both -H; RI and R2 are both phenyl, R3 and R4 are both phenyl, R5 and R6 are both n-hexyl, and R7 and R8 are both -H; R1 and R2 are both phenyl, R3 and R4 are both methyl, R5 and R6 are both methyl, and R7 and R8 are both -H; R1 and R2 are both phenyl, R3 and R4 are both methyl, R5 and R6 are both methyl, and R7 is -H and R8 is methyl; RI and R2 are both phenyl, R3 and R4 are both -H, R5 and R6 are both phenyl, R7 is -H, and R8 is methyl; Rl and R2 are both chlorophenyl, R3 and R4 are both methyl, R5 and R6 are both methyl, and R7 and are both -H.
In Structural Formulas (I)-(VI), Rl and R2 are the same or different; and/or R3 and R4 are the same or different. Preferably, R1 and R2 are the same, and R3 and R4 are the same.
A "straight chained hydrocarbyl group" is an alkylene group, i.e., -(CH2)X , with one or more (preferably one) methylene groups optionally replaced with a linkage group. x is a positive integer (e.g., between 1 and about 10), preferably between 1 and about 6 and more preferably 1 or 2. A "linkage group" refers to a functional group which replaces a methylene in a straight chained hydrocarbyl.
Examples of suitable linkage groups include a ketone (-C(O)-), alkene, alkyne, phenylene, ether (-0-), thioether (-S-), or amine [-N(Ra)]-, wherein Ra is defined below. A preferred linkage group is -C(R7R8)-, wherein R7 and R8 are defined above.
Suitable substitutents for an alkylene group and a hydrocarbaryl group are those which do not substantially interfere with the reactions described herein. R7 and R8 are preferred substituents for an alkylene or hydrocabbyl group.
An aliphatic group is a straight chained, branched or cyclic non-aromatic hydrocarbon which is completely saturated or which contains one or more units of 5 unsaturation. Typically, a straight chained or branched aliphatic group has from 1 to about 20 carbon atoms, preferably from 1 to about 10, and a cyclic aliphatic group has from 3 to about 10 carbon atoms, preferably from 3 to about 8. An aliphatic group is preferably a straight chained or branched alkyl group, e.g, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tent-butyl, pentyl, hexyl, pentyl or octyl, or a 10 cycloalkyl group with 3 to about 8 carbon atoms. A C1-C20 straight chained or branched alkyl group or a C3-C8 cyclic alkyl group is also referred to as a "lower alkyl" group.
Aromatic groups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, thienyl, furanyl, pyridyl, pyrimidy, pyranyl, pyrazolyl, pyrroyl, pyrazinyl, thiazole, oxazolyl, and tetrazole.
Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazole, benzooxazole, benzimidazole, quinolinyl, isoquinolinyl and isoindolyl.
The term "arylene" refers to an aryl group which is connected to the remainder of the molecule by two other bonds. By way of example, the structure of a 1,4-phenylene group is shown below:
Substituents for an arylene group are as described below for an aryl group.
Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered. Examples include tetrahydrofuranyl, tetrahyrothiophenyl, morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, and thiazolidinyl.
The terms "lower alkoxy", "lower acyl", "(lower alkoxy)methyl" and "(lower alkyl)thiomethyl" mean to -O-(lower alkyl), -C(O)-(lower alkyl), -CH2-O-(lower alkyl) and -CH2-S-(lower alkyl), respectively. The terms "substituted lower alkoxy" and "substituted lower acyl" mean -O-(substituted lower alkyl) and -C(O)-(substituted lower alkyl), respectively.
Suitable substituents on an aliphatic group, non-aromatic heterocyclic group.
benzylic or aryl group (carbocyclic and heteroaryl) are those which do not substantially interfere with the ability of the disclosed compounds to enhance the anti-cancer activity of taxol and analogs thereof. A substituent substantially interferes with the ability of a disclosed compound to enhance anti-cancer activity when the enhancement is reduced by more than about 50% in a compound with the substituent compared with a compound without. the substituent. Examples of suitable substituents include -OH, halogen (-Br, -Cl, -I and -F), -ORa, -O-CORa, -CORa, -CN, -NO2, -COOH, -SO3H, -NH2, -NHRa, -N(RaRb), -COORa, -CHO, -CONH2, -CONHRa, -CON(RaRb), -NHCORa, -NRCORa, -NHCONH2, -NHCONRaH, -NHCON(RaRb), -NRcCONH2, -NRcCONRaH, -NR CON(RaR), -C(=NH)-NH2, -C(=NH)-NHRa, -C(=NH)-N(RaRb), -C(=NR )-NH2, -C(=NR )-NHRa, -C(=NR )-N(RaRb), -NH-C(=NH)-NH2, -NH-C(=NH)-NHRa, -NH-C(=NH)-N(RaR), -NH-C(=NRc)-NH., -NH-C(=NRc)-NHRa, -NH-C(=NR )-N(RaRb), -NRdH-C(=NH)-NH2, -NRd-C(=NH)-NHRa, -NRd-C(=NH)-N(RaRb), -NRd-C(=NR )-NH2, -NRd-C(=NRc)-NHRa, -NRd-C(=NR )-N(RaRb), -NHNH2, -NHNHRa, -NHRaRb, -S02NH2a -S02NHRa, -SO2NRaRb, -CH=CHRa, -CH=CRaRb, -CR =CRaRb,-CR =CHRa, -CRc=CRaRb, -CCRa, -SH, -SOkR" (k is 0, 1 or 2) and -NH-C(=NH)-NH2. Ra-Rd are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group, preferably an alkyl, benzylic or aryl group. In addition, -NRaRd , taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group. A non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent. A
substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent.
Also included in the present invention are pharmaceutically acceptable salts of the compounds described herein. The compound of the present invention which possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
Examples of such salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-l -sulfonate, naphthalene-2-sulfonate, mandelate, and the like.
Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.
Taxol, also referred to as "Paclitaxel", is a well-known anti-cancer drug which acts by inhibiting microtubule formation. Many analogs of taxol are known, including taxotere, the structure of which is shown in Figure 4. Taxotere is also referred to as ""Docetaxol". The structure of other taxol analogs are shown in Figures 5-25. These compounds have the basic taxane skeleton as a common structure feature and have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules. Thus, it is apparent from Figures that a wide variety of substituents can decorate the taxane skeleton without adversely affecting biological activity. It is also apparent that zero, one or both of the cyclohexane rings of a taxol analog can have a double bond at the indicated positions. For clarity purposes, the basic taxane skelton is shown below in Structural Formula (VII):
O O O
O
HN 0XXX~=``' O
O p O
O
Double bonds have been omitted from the cyclohexane rings in the taxane skeleton represented by Structural Formula (VII). It is to be understood that the basic taxane skeleton can include zero or one double bond in one or both cyclohexane rings, as indicated in Figures 5-25 and Structural Formulas (VIII) and (IX) below. A
number of atoms have also omitted from Structural Formula (VII) to indicate sites in which structural variation commonly occurs among taxol analogs. For example, substitution on the taxane skeleton with simply an oxygen atom indicates that hydroxyl, acyl, alkoxy or other oxygen-bearing substituent is commonly found at the site. It is to be understood that these and other substitutions on the taxane skeleton can also be made without losing the ability to enhance and stabilize microtubule formation. Thus, the term "taxol analog" is defined herein to mean a compound which has the basic taxol skeleton and which promotes disassembly of microtubules.
Typically, the taxol analogs used herein are represented by Structural Formula (VIII) or (IX):
R12 p s",XXR2o R1o N ONX
H
OR21 R1s >-R,6 O
(VIII).
O
HN 0XXX~=``' O
O p O
O
Double bonds have been omitted from the cyclohexane rings in the taxane skeleton represented by Structural Formula (VII). It is to be understood that the basic taxane skeleton can include zero or one double bond in one or both cyclohexane rings, as indicated in Figures 5-25 and Structural Formulas (VIII) and (IX) below. A
number of atoms have also omitted from Structural Formula (VII) to indicate sites in which structural variation commonly occurs among taxol analogs. For example, substitution on the taxane skeleton with simply an oxygen atom indicates that hydroxyl, acyl, alkoxy or other oxygen-bearing substituent is commonly found at the site. It is to be understood that these and other substitutions on the taxane skeleton can also be made without losing the ability to enhance and stabilize microtubule formation. Thus, the term "taxol analog" is defined herein to mean a compound which has the basic taxol skeleton and which promotes disassembly of microtubules.
Typically, the taxol analogs used herein are represented by Structural Formula (VIII) or (IX):
R12 p s",XXR2o R1o N ONX
H
OR21 R1s >-R,6 O
(VIII).
R1s (IX).
Rio is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group,'-SR19, -NHR19 or -OR19.
R11 is a lower alkyl group, a substituted lower alkyl group, an aryl group or a substituted aryl group.
R12 is -H, -OH, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, -O-C(O)-(lower alkyl), -O-C(O)-(substituted lower alkyl), -O-CH2-O-(lower alkyl) -S-CH2-O-(lower alkyl).
R13 is -H, -CH3, or, taken together with R14, -CH2-.
R14 is -H, -OH, lower alkoxy, -O-C(O)-(lower alkyl), substituted lower alkoxy, -O-C(O)-(substituted lower alkyl), -O-CH2-O-P(O)(OH)2, -O-CH2-O-(lower alkyl), -O-CH2-S-(lower alkyl) or, taken together with R20, a double bond.
R15 -H, lower acyl, lower alkyl, substituted lower alkyl, alkoxymethyl, alkthiomethyl, -OC(O)-O(lower alkyl), -OC(O)-O(substituted lower alkyl), -OC(O)-NH(lower alkyl) or -OC(O)-NH(substituted lower alkyl).
R16 is phenyl or substituted phenyl.
R17 is -H, lower acyl, substituted lower acyl, lower alkyl, substituted, lower alkyl, (lower alkoxy)methyl or (lower alkyl)thiomethyl.
R18 -H, -CH3 or, taken together with R17 and the carbon atoms to which R17 and R18 are bonded, a five or six membered a non-aromatic heterocyclic ring.
R19 is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group.
R20 is -H or a halogen.
R21 is -H, lower alkyl, substituted lower alkyl, lower acyl or substituted lower acyl.
Preferably, the variables in Structural Formulas (VIII) and (IX) are defined as follows: R10 is phenyl, tert-butoxy, -S-CH2-CH-(CH3)2, -S-CH(CH3)3, -S-(CH2)3CH3, -O-CH(CH3)3, -NH-CH(CH3)3, -CH=C(CH3)2 orpara-chlorophenyl;
R11 is phenyl, (CH3)2CHCH2-, -2-furanyl, cyclopropyl orpara-toluyl; R12 is -H, -5 OH, CH3CO- or -(CH2)2-N-morpholino; R13 is methyl, or, R13 and R14, taken together, are -CH2-;
R14 is -H, -CH2SCH3 or -CH2-O-P(O)(OH)2; R15 is CH3CO-;
R16 is phenyl; R17 -H, or, R17 and R18, taken together, are -0-CO-0-;
R18 is -H; R20 is -H or -F; and R21 is -H, -C(O)-CHBr-(CH2)13-CH3 or -C(O)-10 (CH2)14-CH3; -C(O)-CH2-CH(OH)-COOH, -C(O)-CH2-O-C(O)-CH2CH(NH2)-CONH2, -C(O)-CH2-O--CH2CH2OCH3 or -C(O)-O-C(O)-CH2CH3.
A taxol analog can also be bonded to or be pendent from a pharmaceutically acceptable polymer, such as a polyacrylamide. One example of a polymer of this type is shown in Figure 26. The term "taxol analog", as it is used herein, includes 15 such polymers.
The disclosed compounds are enhancers of the anti-cancer activity of taxol and taxol analogs. A compound enhances the anti-cancer activity of taxol or a taxol analog when the activity of taxol or the taxol analog is greater when administered in combination with the compound than when administered alone. The degree of the increase in activity depends upon the amount of compound administered. The compounds of the present invention can therefore be used in combination with taxol or taxol analogs to treat subjects with cancers. Examples include colon cancer, pancreatic cancer, melanoma, renal cancer, sarcoma, breast cancer, ovarian cancer, lung cancer. stomach cancer, bladder cancer and cervical cancer.
A "subject" is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
In order to achieve an enhancement of the anti-cancer activity of taxol and taxol analogs, an effective amount of a compound of the present invention and an effective amount of taxol or analog of taxol are administered to the subject.
With respect to taxol or an analog of taxol, an "effective amount" is a quantity in which anti-cancer effects are normally achieved. With respect to a compound of the present invention, an "effective amount" is the quantity in which a greater anti-cancer effect is achieved when the compound is co-administered with taxol or a taxol analog compared with when taxol or the taxol analog is administered alone. The compound and taxol (or taxol analog) can be co-administered to the subject as part of the same pharmaceutical composition or, alternatively, as separate pharmaceutical compositions. When administered as separate pharmaceutical compositions, the compound or the present invention and taxol (or taxol analog) can be administered simultaneously or at different times, provided that the enhancing effect of the compound is retained.
The amount of compound and taxol (or taxol analog) administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of cancer.
The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for taxol and taxol analog are well known and typically range from between about 1 mg/mm2 per day and about 1000 mg/mm2 per day, preferably between about 10 mg/mm2 per day and about 500 mg/mm2 per day.
Effective amounts of a compound of the present invention typically range between about 1 mg/mm2 per day and about 10 grams/mm2 per day, and preferably between 10 mg/mm2 per day and about 5 grams/mm2.
The disclosed compounds are administered by any suitable route, including, for example, orally in capsules, suspensions or tablets or by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compounds can also be administered orally (e.g., dietary), topically, by inhalation (e.g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the type of cancer to be treated.
Oral or parenteral administration are preferred modes of administration. Suitable routes of administration of taxol and taxol analogs are well known in the art and include by parenteral administration, as described above for the compounds of the present invention. Suitable routes of administration for taxol and analogs thereof are well known and include inter alia parenteral and oral administration.
The disclosed compounds can be administered to the subject in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition for treatment of cancer. Formulation of the compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule).
Suitable pharmaceutical carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextrasn) are known in the art (Baker, et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).Suitable formulations for taxol and taxol analogs are well known in the art.
The disclosed compounds can be prepared according to methods described in Examples 1-12 and also according to methods described in U.S. Patent No.
6,825,235.
The present invention is illustrated by the following examples, which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1 S
S
S OH R1H2 N,NH2 NaOH / R' O R
R
Preparation of Thiobenzoic acid N-nnethylhydrazide: Thiobenzoic acid N-methylhydrazide were prepared in 88% yield by slight modification of the pricy art (Acta Chem. Scand. 1961, 1087-1096); 'H NMR (CDC13) 5 3.3, (s, 3H), 6:0 (s, 2H), 7.3-7.4 (m, 5H); ESMS calcd (C8H1oN2S): 166.1; found: 167.1 (M+H)+.
Example 2 Preparation of Thiobenzoic acid N-methyllnydrazide: Bromobenzene (1.6g, 10 mmol) was added into 25 ml anhydrous THE solution containing magnesium.
powder (0.3g, 12.5 mmol), and refluxed for 2 In. After it was cooled, the clear reaction solution was added into carbon disulfide (1 mi, 16.8 mmol) at 0 C, and stirred for 30 min at rt. The resulting mixture was then added into methylhydrazine (1.6 ml, 3Ommol) at 0 C, and stirred for another 2 hours. To this solution was added water (15 ml) and extracted with EtOAc (30 ml x 3). The organic solution was concentrated to minimum volume, and subjected to silica gel column chromatography (eluant: 1:3 - 1:1 ethyl acetate : hexanes) to give thiobenzoic acid N'-methyl hydrazide (0.72 g, total yield: 48 %). 'H NMR (CDC13) 8 3.3 (s, 3H), 6.0 (s, 2H), 7.3-7.4 (m, 5H); ESMS calcd (C8HION2S): 166.1; found: 167.1 (M+H)+.
Example 3 H RCOOH; DCC; DMAP (cat) R rO Lawesson's R / S
N 30. H3C' ,NH2 CH2C12 H3C'N=NH2 H3C'N.
0 C to RT
hiobenzoic acid N-methylhydrazine: DCC (4.5 g, 21.8 Preparation of 2,5-Dimethoxyt mmol) was added in one portion to a solution of 2,5-dimethoxybenzoic acid (3.6g, mol), methylhydrazine (1.2 ml, 23 mmol) and DMAP (30 mg, cat.) in CH2CI2 (60 ml) cooled in an ice bath. The reaction mixture was stirred overnight at room 15 temperature. The slurry was cooled at -20 C for 1 h and filtered. The solution was evaporated and the residue was dried in vacuum. The resulting crude product was dissolved in toluene (50 ml). To this solution was added Lawesson's reagent (5.8 g, 14 mmol). The mixture was refluxed for 40 min, cooled to room temperature, and directly subjected to silica gel column chromatography (eluent: 25 20 % to 35 % ethyl acetate in hexanes) to give the 2,5-dimethoxythiobenzoic acid N-methylhydrazide (3.7 g, yield: 82%) as off-white solid. 1H NMR (300MHz, CDCl3):
b 6.88-6.80(m, 3H), 5.46 (s, 2H), 3.84(s, 3H), 3.82 (s, 3H), 3.28(s, 3H).
Example 4 S HO R3 R2 off DCC, DMF R. , N R3 R2 N.
R~N'NH2 + R N N R Y's-R1 0 0 Method A RI 0 0 R1 Preparation ofN-Malonyl-bis[N'-methyl-N'-(thiobenzoyl)hydrazidel: To a stirred solution of thiobenzoic acid N-methylhydrazide (0.166 g, 10 mmol), HOBt'H20 (0.15 g, 11 mmol) and malonic acid (0.052 g, 5 mmol) in DMF (2 mL) was added DCC (0.22 g, 10.7 mmol) at 0 C. The resultant suspension was stirred at 0 C
for 1 h and at room temperature for 3 h. Precipitated material was filtered off and washed with EtOAc (3 x 15 mL). Combined filtrate and washings was washed successively with H2O (2 x 20 mL), 5% citric acid (20 mL),H20 (20 mL), Saturated NaHCO3 (20 mL) and brine (20 mL). After being dried over Na2SO4, the solvent was removed under reduced pressure to afford the crude product as a yellow solid, which was washed with warm EtOAc. 0.16 g (yield 80%) of pure product was obtained as a yellow powder. Rf 0.3 (Hexane/EtOAc 1:1 vlv); 1H NMR (CDC13) S 3.1 - 3.8 (m, 6H), 3.4 (s, 2H), 7.1- 7.45 (m, 10 H), 9.5 - 10.5 (m, 1 H) ppm; ESMS caled (C19H2ON402S2): 400.1; found: 399.1 (M-H)+.
Preparation of N-(2-Meth llmalonyl-bis {N'-methyl-N'-[(2,5-dimethoxy)thiobenzoyllhydrazidel :
O S H H S 'O
N.N N , .
,O ~'O
DCC (4 g, 19 mmol) was added to a solution of 2,5-dimethoxythiobenzoic acid N-methylhydrazide (3.7 g, 16.4 mmol) and 2-methylmalonic acid (2 g, 17 mmol) in DMF
(20 ml) with stirring at 0 C. The reaction mixture was stirred for lh at room temperature.
The slurry was cooled at -20 C for 1 h and filtered. The filtrate was diluted with EtOAc (300 ml), washed with water (50 ml x 3), dried with Na2SO4. The EtOAc solution was concentrated to minimum volume, and subjected to silica gel column chromatography (eluent: 1:4 to 2:1, ethyl acetate: hexanes) to give the title compound (3.5 g, 80 %) as yellow powder. 'H NMR (CDC13) 6 10.12-9.14 (214), 7.12-6.81 (m, 6H), 4.01-3.78(m, 6H), 3.75-3.22(m, 6H), 2.82-2.62(m, 1H), 1.12-0.11(m,3H); ESMS cacld (C24H30N406S2):534.16; found: 535.1 (M+H).
Example 5 CI~CISI RH 3 R2 H S
RN,NH2 0 O RJ~N,N\2/N,N1~1 R
R, R1 0 0 R, Preparation of N-Malonyl-bisfN'-methyj-N'-(thiobenzoyl)hydrazidel: To a solution of thiobenzoic acid N-methylhydrazine (10 g) stirred at 0 C were added subsequently triethylamine (8.5 mL) and malonyl dichloride (3.05 mL). The reaction mixture was stirred for 10 min, washed with water (3x50 mL), dried over sodium sulfate and concentrated. Purification by recrystallization from methylene dichloride (35 mL) gave the product as light yellow crystals (9.0 g, 75%) which was identical to the product 5 obtained in Example 6.
Example 6 S PhO\ K /OPh S R3 R2 S
RNNH2 O O R kN,N N,NR yNr R1 Method B R, 0 0 R1 Preparation of N-Malonyl-bis[N'-methyl-N'-(thiobenzoyl)hydrazidel: A stirred solution of thiobenzoic acid N-methylhydrazide (1.66 g, 10 mmol) and diphenyl malonate (1.30 g, 5.08 mmol) in dry THE (100 mL) was heated to reflux for 72 h. Volatile components were then removed under reduced pressure. The crude product was purified by column chromatography on silica gel using a mixture of hexane and EtOAc as eluant (gradient from 4:1 v/v to 1: 1 v/v). 1.07 g (51% yield) of pure product N-malonyl-bis[N'-methyl-N'-(thiobenzoyl)hydrazide] was obtained as a yellow powder. Physical property was identical to that obtained in Example 5.
Example 7 S
NH DCC, DMF 0--ir O O
N 2 0 0 N,N~ULO
S H
H OX~O
0' 1) TFA
2) DCC, DMF 0--r N'N-kIANA
S S H H g 0, 'O N.NH2 A slurry of thiobenzoic acid N-methylhydrazide (1.0 g, 6 mmol), mono-tert-butyl malonate (1.0 mL, 6 mmol), HOBt.H20 (0.98 g, 7.2 mmol), and DCC (1.34 g, 6.5 mmol) in DMF (5 mL) was stirred at 0 C for 3 h and then at room temperature for 3h.
Precipitated material was filtered off and washed with EtOAc (3 x 20 mL).
Combined filtrate and washings was washed successively with H2O (2 x 20 mL), 5% citric acid (20 mL), H2O (20 mL), Saturated NaHCO3 (20 mL) and brine (20 mL). After being -dried over Na2SO4, the solvent was removed under reduced pressure to afford the crude product as a solid, which was washed with Et2O. 0.94 g (yield 51 %) of pure product N'-Methyl-N'-thiobenzoyl-hydrazinocarbonyl)-acetic acid text-butyl ester was obtained as a yellow powder. 1H NMR (CDC13) S 1.6-1.7 (ds, 9H), 3.1-4.1 (m, 5 H), 7.3-7.7 (m, 5H), 9.7-10.3 (ds, 1H)ppm; ESMS calcd (C15H2ON203S): 308; found: 307 (M-H)+.
A solution of N'-methyl-N'-thiobenzoyl-hydrazinocarbonyl)-acetic acid tert-butyl ester (0.19g, 0.6 mmol) and TFA (0.12 mL, 1.6 mmol) in dry DCM (10 mL) was stirred at 10 C - 15 C for 12 h (reaction was monitored by TLC). Volatile components were removed under reduced pressure (bath temperature below 5 C). After being dried in vacuo, DMF (3 mL) was added followed by the addition of DCC (0.13 g, 0.6 mmol), HOBt'H20 (93 mg, 0.7 mmol) and thio-2,5-dimethoxybenzoic acid N-methylhydrazide (0.13 g, 0.57 mmol). The resultant solution was stirred at 0 C for half an hour and then at room temperature for 3h. Precipitated material was filtered off and washed with EtOAc (3 x 10 mL). Combined filtrate and washings was washed successively with (2 x 10 mL), 5% citric acid (10 mL), H2O (10 mL), Saturated NaHCO3 (20 mL) and brine (20 mL). After being dried over Na2SO4, the solvent was removed under reduced pressure to afford the crude product as an oil, which was purified by SGC (4:1 hexane/EA to 2:1 EtOAc/Hexane). 0.14 g (yield 53%) of pure product was obtained as a yellow powder. 'H NMR (CDC13) 6 3.1-3.9 (m, 18H), 6.7-7.4 (m, 9H)ppm; ESMS
calcd (C21H24N404S2): 460.1; found: 461.1 (M+H)+.
Example 8 o O
H EtOOEt H 0 0 H
N,NH2 N N
N N-R Xylene, reflux H H
1. anhydride R2 S S R2 )t,_A
2. Na2S; HCI H H N t Preparation of N- N-malonyl-bislN'-phenyl-N'-(thiobenzoyl)hydrazidel a/N, )LN N
H H
A mixture of phenylhydrazine (30 mL) and ethyl malonate (in xylene (150 mL) was heated to reflux overnight. The reaction was cooled to room temperature. The precipitates were collected via filtration and washed with ethanol to give N-malonyl-bis(N'-phenylhydrazide) as a white solid (14 g). The hydrazide (3.4 g) was suspended in benzoic anhydride (50 g) with warming. To it was added dropwise perchloric acid (57%
in water, 3 mL). The reaction mixture turned to clear solution initially and then quickly solidified. After standing at room temperature for 1 h, ether (50 mL) was added. The resulting slurry was filtered and washed with ether (2 x 00 mL) to give the perchlorate salts as a white solid (5.7 g). The salts were taken into acetone and added as a slurry over 5 min to Na2S (0.6 M in water, 90 mL) stirred at room temperature. After 30 min, the reaction was acidified with HC1(c) to afford a yellow slurry. The solid was collected via filtration and washed with water (20 mL) and ether (2x25 mL) to give N-malonyl-bis[N'-phenyl-N'-(thiobenzoyl)hydrazide] as an off-white solid (3.6 g). 1H NMR
(CDC13): b 7.2 (m, 20H); 3.5 (br s, 2H). MS calcd for C29H24N402S2: 524.13: Found: 525.1 (M+H).
Example 9 S H R3 R2 H S MeOH, DEAD SI~ R3 R2 S
RAN,N~N,NAR RJ)N'N s N,NAR
R1 0 0 R, R, 0 0 R, Preparation of N-Malonyl-bis[N-methyl-N'-phenyl-N'-(thiobenzoyl)hydrazidel To a stirred solution of N-malonyl-bis[N'-phenyl-N'-(thiobenzoyl)hydrazide]
(180 mg, 0.34 mmol), MeOH (22 uL) and triphenylphosphine (200 mg, 0.64 mmol) in dry THF(10 mL) was added a solution of DEAD (0.12 mL) in THE (3 mL) dropwise.
The resultant orange solution was stirred at room temperature for 12 h. After removal of the volatile components, the crude product was purified by SGC (3:1 Hexane/EtOAc) to afford 98 mg (52% yield) of the title compound as syrup. 'H NMR (CDC13) S 3.3-4.5 (m, 8H), 7.1-7.8 (m, 20 H)ppm; ESMS calcd (C31H28N402S2): 552; found: 551 (M-H)+.
Example 10 O O i l Lawessen's Reagent N PhH, reflux, lh 0-r N NA,,,~LH S
S H S S
N.N,,JLN.N
S H H S
A stirred mixture of N-malonyl-bis[N'-phenyl-N'-(thioacetyl)hydrazide) starting material (0.1 g, 0.25 mmol) and Lawesson's reagent (0.15 g, 0.37 mmol) in dry benzene (20 mL) was heated to reflux for 1 h. After being cooled to room temperature, the mixture was filtered through a layer of silica gel, washed with THE (2 x 15 mL). The filtrate and washings were combined and concentrated under reduced pressure.
Flush column chromatography on silica gel (hexane to 4:1 hexane/EtOAc to 2:1 hexane/EtOAc) afforded N-bisthiomalonyl-bis[N'-phenyl-N'-(thioacetyl)hydrazide as a clear syrup (16 mg, 15%). 'H NMR (CDCl3) 6 3.80-3.95 (m, 8H), 7.02-7.30 9m, 10 H).
ESMS calcd (C,9H2QN4S4): 432.06; found: 433.0 (M+H)+.
Example 11 The compounds shown below were prepared by the procedures described above.
Analytical data is provided for these compounds.
S S
NN NON
o 0 1 1, IH NMR (CDC13) 8 3.1- 3.8 (m, 6H), 3.4 (s, 2H), 7.1- 7.45 (m, 10 H), 9.5 -10.5 (m, 1H) ppm; ESMS calcd (CI9H2ON402S2): 400.1; found: 399.1 (M-H)+.
S H H S
N'NN,N
'HNMR (CDC13) 8 1.0-1.35 (m, 6H), 3.0-4.3 (m, 6H), 7.05-7.40 (m, 1OH), 9.1-10.1 (m, 2H); ESMS cacld (C21H24N4O2S2): 428.8; found: 427 (M-H)+. Anal Cale For C21H24N402S2 (428.13) C, 58.85; H, 5.64; N, 13.07; S, 14.96. Found: C, 58.73;
H, 5.62;
N, 12.97; S, 14.96.
Qinic H H N,N N,N 20 'H NMR (CDCl3) 8 0.7-1.0 (m, 6H), 1.4-1.9 (m, 4H), 3.1-4.2 (m, 6H), 7.1-7.4 (m, 1OH), 8.9-10.2 (m, 2H) ppm; ESMS (C23H28N402S2): 456.1; found: 455.1 (M-H)+.
S H H S
N.N N-N
O
mp 141 - 143 C; 'H NMR (CDC13) 8 0.6-1.05 (m, 6H), 1.1-1.9 (m, 8H), 3.0-4.2 (m, 6H), 7.0-7.35 (m, 1OH), 8.9-11 (ms, 2H). ESMS (C25H32N402S2): 484.2; found:
483.1 (M-H)+. Anal Cale For C25H32N402S2 (484.2) C, 61.95; H, 6.65; N, 11.56; S, 13.23.
Found: C, 61.98; H, 6.52; N, 11.26; S, 13.16.
S H I H S
N,N\~N,N
\N
'H NMR (DMSO-d6) S 0.4-0.9 (dd, 3H, J = 7), 2.7 (q, 1H), 3.1 - 3.6 (m, 6H), 7.1 - 7.5 (m, 1OH), 10.9 (br, 2H)ppm; ESMS (C20H22N402S2): 414; found: 413 (M-H)+.
S H H S
\ N.N N,N
'~y 'H NMR (CDC13) 6 0.5 (t, 3H, J= 7), 1.1-1.6 (m, 2H), 2.7 (t, 1H, J=7),3.1-3.3 (m, 6H), 7.0-7.3 (m, 1OH), 10.25 (s, 2H)ppm; MS (C21H24N402S2): 428.1; found:
427.1 (M-H)+.
S H H S
el N,N ;ry N=N 15 0 0 1H NMR (CDC13) 6 0.5 (d, 6H, J =7), 0.9-1.2 (m, 1H), 3.0-41 (m, 7H), 7.1-7.4(m, l OH), 10.3 (s, 2H)ppm; ESMS (C22H26N402S2): 442.1; found: 441.1 (M-H)+.
S H H S
N,N N.,N \
~~ I 0 0 ~~
'H NMR (CDC13) 6 0.4-1.3 (m, 5H), 1.5-1.8 (m, 2H), 3.0-3.7 (m, 6H), 7.1-7.5 (m, 10H), 11 (s, 2H) ppm; ESMS (C23H28N402S2): 456.1; found: 455.1 (M-H)+.
S S
H H
{N0 N N,N
I O O I
'H NMR (CDC13) 6 2.1 (d, 2H, J =7), 2.9 (t, 1H, J =7), 3.1-3.5 (m, 6H), 6.8-7.4 (m, 15 H), 11 (s, 2H)ppm; ESMS (C26H26N4O2S2): 490.1; found: 489.1 (M-H)+.
S H ll H S
N'NN,N
o rr0II
'H NMR (CDC13) 8 0.4 (d, 3H, J = 7), 1.0-1.4 (m, 6H), 2.75 (q, 1H), 3.0-4.3 (m, 4H), 7.1-7.4 (m, IOH), 10.6 (s, 2H); ESMS Calc For (C22H26N402S2): 442.1; found:
441.1 (M-H)+; Anal Calc For C22H26N402S2 (442.15) C, 59.70; H, 5.92; N, 12.66; S, 14.49. Found:
C, 59.64; H, 5.92; N, 12.59; S, 14.47.
S H H S
N'N N.N
~ I
\ I
'H NMR (DMSO-d6) S 3.20 (br, 2H), 7.1-7.6 (m, 20 H), 11.5 (s, 2H) ppm; ESMS
calcd (C29H24N402S2): 524.1; found: 523.1 (M-H)+.
S H H S
\ N'N(N'N
~O / I ~III IIOII I
'H NMR (CDC13) 8 3.0-4.3 (m, 14H), 6.6-7.5 (m, 8H), 10.4 (s, 211) ppm; ESMS
calcd (C2 1 H24N4O2 S 2) : 460.2; found: 461.2 (M+H)+.
S H H S
\ N.N~N.N \
Cl I I O O I CI
'H NMR (CDC13) 6 2.65-3.60 (in, 8H), 7.2-7.4 (m, 8H), 11.1 (br, 2H); ESMS
calcd (C19H18C12N4O2S2): 468.0; found: 467.9 (M-H)+.
S H H S
el N'N N,N 25 0 0 1 'H NMR (CDC13) S 0.4 (d, 3H, J = 7), 2.7 (q, 1H, J = 7), 3.0-3.8 (m, 6H), 7.2-8.2 (m, 8H), 10.5-10.7 (ms, 2H) ppm; ESMS calcd (C20H2OC12N402S2): 482.0; found: 481.0 (M-H)+.
s H H S
WN`^/N.N
O O I
'H NMR (CDC13) 6 2.9-3.8 (m, 6H), 7.3-7.7 (m, 4H), 8.0-8.3 (m, 4H), 10.9 (s, 2H);
ESMS calcd (C10H18N606S2): 490.0; found: 489.0 (M-H)+.
S H H S
I ~
eo N,NN,N
/
O O O b 'H NMR (CDC13) S 3.1-3.9 (m, 14H), 6.7-7.8 (m, 8H), 9.0-10 (m, 2H) ppm; ESMS
calcd (C21H24N404S2): 460.1; found: 459.1 (M-H)+.
S H H S
O~1 i0 (SBR-11-5032): 'H NMR (CDC13) 6 3.0-3.9 (m, 14H), 6.7-7.3 (m, 8H), 9.0-10 (m, 2H) ppm; ESMS calcd (C21H24N404S2): 460.1; found: 459.1 (M-H)+.
S H H S
c N,N N.N O Iry 20 o o 111 /
'H NMR (acetone-d6) 6 3.5 (s, 2H), 6.45 (d, 2H, J = 5), 6.9 (d, 2H, J = 5), 7.2-7.6 (m, 12H), 10.6 (s, 2H) ppm; ESMS calod (C25H2ON404S2): 504.1; found: 503.1 (M-H)+.
CI S H H. S CI
N, {1 N
Np O O l pN
'H NMR (DMSO-d6) S 2.60 (s, 6H), 3.05 (s, 6H), 3.40 (s, 2H), 7.15-7.50 (m, 8H)ppm;
ESMS calcd (C27H24C12N604S2): 630.1; found: 629.1 (M-H)+.
N=NrN=N 1`110 ~,O -0 'H NMR (CDC13) 8 10.06-8.82 (2H), 7.16-6.81(m,6H), 4.01-3.81(m, 6H), 3.78-3.11(m,6H), 2.81-2.58(m,2H): ESMS cacld (C23H28N406S2): 520.15; found: 521 (M+H).
"1 0 S H H S 0 ~10i N,N N.N O"
0 0 'H NMR (CDC13) S 10.38-9.01 (2H), 7.12-6.82 (m, 6H), 3.92-3.78(m, 12H), 3.75-3.06(m, 6H), 2.61-2.51 (m, 2H); ESMS caccd (C23H28N406S2): 520.15; found: 521 (M+H).
1~ O S H H S 1-1 O
"0 N.N N-N 0"
'H NMR (CDC13) 3 9.45-8.63 (2H), 7.18-6.81 (m, 6H), 4.01-3.80(m, 6H), 3.78-3.24(m, 6H), 2.62-2.50(m, IH), 1.74-0.11 (m, 3H); ESMS caccd (C24H3oN406S2):534.16;
found:
535 (M+H).
S H H S
N r,,~,N.N O O
'H NMR (CDC13) S 10.19-8.61 (2H), 7.26-6.52(m, 6H), 3.81-3.08(m, 8H), 3.01-2.88(m, 12H). ESMS cacld (C23H30N602S2): 486.19; found: 487 (M+H).
O S H H S "1 O
N~~N.
N" N
Cl CI
'H NMR (CDCl3) 8 9.92-8.80 (2H), 7.41-6.72 (m, 6H), 4.01-3.81(m,6H), 3.80-3.15 (m,6H), 2.76-2.42(m, 2H); ESMS cacld (C21H22C12N404S2):528.05; found:
529(M+H).
O S H H S
N.N N.N
O O CI CI
'H NMR (CDC13) 8 10.21-9.02(2H), 7.60-6.81 (m, 6H), 4.14-3.88(m, 6H), 3.87-3.18 (m,6H), 2.84-2.65(m, 1H),1.10-0.16 (m, 3H); ESMS cacld (C22H24C12N404S2):
542.06;
found: 543(M+H).
F S H H S F
N.N N.N
O O ~
F F
'H NMR (CDC13) 6 10.02-9.20 (2H), 7.63-7.01 (m, 6H), 4.21-3.22(m, 6H), 1.88-1.36 (m, 2H); ESMS cacid (C19Hi6F4N402S2): 472.07; found: 473 (M+H).
F S H H S F
NN NN
O
F F
1H NMR (CDCl3) 6 7.93-7.61 (2H), 7.40-6.92 (m, 6H), 3.98-3.41 (m, 6H), 2.19-0.93 (m, 4H); ESMS cacld (C20H,8F4N402S2): 486.08; found: 487 (M+H).
Cl S H H S Cl N.N N.N
O O
CI CI
'H NMR (CDC13) 6 10.12-9.21(2H), 7.67-7.23 (m, 6H), 3.94-3.22 (m, 6H), 2.01-1.21 (m, 2H); ESMS cacld (C,9H16C14N402S2): 535.95; found: 537(M+H).
Cl S H H S Cl N.N NN
O O l CI CI
'H NMR (CDC13) 6 7.78-7.23 (2H),'4.56-3.10 (m, 6H), 2.34-1.12 (m, 4H); ESMS
cacld (C20H1 sC14N402S2): 549.96; found: 551 (M+H).
O S H H S "O
1 11 N.N N.N
l O O O O b I
1H NMR (CDCI3) S 9.92-9.01 (2H), 7.38-7.15 (m,3H), 6.66-6.51 (m,3H), 3.98-3.75 (m,12H), 3.72-3.21(m,6H), 2.01-0.42 (m, 4H); ESMS cacld (C24H3oN406S2):534.16;
found: 535 (M+H).
S H H S
N.N r,-,YN.N
l 'H NMR (CDC13) S 10.51-9.82 (2H), 7.42-6.80 (m, 6H), 3.92-3.04(m, 6H), 2.60-1.21 (m, 14H); ESMS cacld (C23H28N402S2): 456.17; found: 457(M+H).
S H H S
NN N.N
'HNMR (CDC13) S 10.51-8.82 (2H), 7.11-6.89 (m, 6H), 3.81-3.02,(m, 6H), 2.40-1.02 (m, 16H); ESMS cacld (C24H3oN402S2): 470.18; found: 471(M+H).
O S H H S "0 N N~~N.N
J O O J i 'HNMR (CDC13) 8 9.86-8.42 (2H), 7.01-6.6 (m, 6H), 4.18-3.51 (m, 16H), 3.22-2.26 (2H), 1.40-1.04 (m, 6H); ESMS cacld (C25H32N406S2):548.18; found: 547 (M-H).
0 S H H S. O
N,NYcN.N
I~ J J 0 of I~
~O '10 'HNMR (CDC13) 6 9.99-8.41 (2H), 7.01-6.68 (m, 6H), 4.18-3.56 (m, 16H), 1.40-0.02 (m, 1OH); ESMS cacld (C26H34N406S2): 562.19; found: 561(M-H).
N.NN.N
'HNMR (CDC13) 6 10.12-8.82 (2H), 7.03-6.62 (m, 6H), 4.21-3.87 (m, 8H), 3.84-3.01(m, 6H), 2.71-2.42 (m, 2H), 1.56-1.21 (m, 12H); ESMS cacld (C27H36N406S2): 576.21;
found: 577(M+H).
N'N N=N 11-cr 1 0 0 1 i 1H NMR (CDC13) 6 9.81-8.79 (2H), 7.01-6.64 (m, 6H), 4.21-3.81(m, 8H), 3.80-3.22 (m, 6H), 1.54-1.20 (m, 13H), 1.01-0.16 (m, 3H); ESMS cacid (C28H38N406S2): 590.22;
5 found: 591(M+H).
S S
a O O
/N.NIN.N
H H
1H NMR (DMSO-d6): 6 8.25 (d, J=8.1 Hz, 4H), 7.50 (d, J=8.1 Hz, 4H), 3.7-3.3 (m, 8H);
10 ESMS cacid for C19H18N606S2: 490.1; Found: 489.0 (M-H).
NC CN
, I S S
O O
N.Nfil-A N'N
H H
'H NMR (CDC13): 5-10.25 (m, 2H), 7.7-7.4 (m, 8H), 3.7 (m, 2H), 3.35 (m, 61H);
ESMS
cacid for C21H18N602S2: 450.1; Found: 449.0 (M-H).
N N
~- I S S
N.NfilA N=N
H H
1H NMR (CDC13): 8 8.2 (s, 2H), 7.7-7.5 (m, 4H), 3.7-3.4 (m, 8H), 2.9-2.8 (m, 6H);
ESMS cacid for C19H22N602S2: 430.1; Found: 431.1 (M+H).
CN CN
6 S S ~
N.NIN.N,,,~
H H
'H NMR (CDC13): 6 10.0-9.2 (m, 2H), 7.9-7.45 (m, 8H), 4.0-3.4 (m, 8H); ESMS
cacld for C21H18N602S2: 450.1; Found: 451.0 (M+H).
F F
N'N1N'NI--, H H
'H NMR (CDC13): 6 10.1-9.4 (2H), 7.5-7.2 (m, 8H), 3.9-3.3 (m, 8H); ESMS cacld for C 14H18F2N402S2: 436.1; Found: 437.1 (M+H).
N\ // n \
'H NMR (CDC13): 6 3.3 (s, 2H), 3.6 (s, 6H), 5.25 (s, 4H), 7.05-7.3 (m, 16H), 7.6 (s, 2H), 7.9 (d, 2H, J = 6), 10.56 (s, 2H)ppm; ESMS calcd (C37H34N602S2): 658.2; found:
659.2 (M+H)+.
s N 0 H/
I
0 s 1H NMR (DMSO) 6 11.98 (2H), 7.44-7.12 (m, 10H), 3.69-3.14(s, 6H). ESMS cacld (C18H18N402S2): 386.09: found: 387.1 (M+H).
o H"r~. I
o 'H NMR (CHC13) 6 9.48-8.55 (2H), 7.56-7.20(m, 10H), 3.80-3.31(m, 6H), 2.88-2.22(m, 4H). ESMS cacld (C20H22N402S2): 414.12; found: 415.1 (M+H).
S S -(D~N-NH HN-N
O
IH NMR (300 MHz, CDC13) 6 10.21-9.91 (m, 2H), 8.06-7.32 (m, 14H), 3.91-3.56 (m, 6H). ESMS cacld (C24H22N402S2): 462.12; found: 463 (M+H).
S
Crj',N - N H
S
O
HN-N
'H NMR (300 MHz, DMSO-d6) 6 11.60-11.40 (m, 2H), 7.48-6.46 (m, 12H), 3.64-3.3.30(m, 6H). ESMS cacld (C20H2ON402S2): 412.10; found: 413 (M+H).
S
NN~\
O N N
S
'HNMR (300 MHz, CDC13) 6 7.58-7.20 (m, 12H), 3.68-3.20 (m, 6H). ESMS cacld (C20H2ON402S2): 412.10; found: 413 (M+H).
S
N-N\
S O
NN
'H NMR (300 MHz, CDC13): S 9.65-8.70 (2H), 8.01-7.21(m, 14H), 3.84-3.40(in, 6H).
ESMS cacld (C24H22N402S2): 462.12: found: 463 (M+H).
Orsoos1.O
N)1'-A \~H HN ~/
'H NMR (CDC13): 6 7.2 (m, 18H); 3.5 (br s, 2H); 2.4 (br s, 6H). MS calcd for C31 H28N402S2: 552.2: Found: 553.2 (M+H).
H3C--r O oy O O
I S S
O IOI
\ I N H~~H,N ~ i 1H NMR (CDC13): 8 7.5 (br s, 18H), 3.4 (br s, 2H), 2.45 (s, 6H). ESMS cacld for C33H28N406S2: 640.1; Found 641.1 (M+H).
: S S
/ II N,HAXAHN ( ~
1H NMR (CDC13-D20): 6 7.45-7.15 (m, 20 H), 1.6 (br s, 6H). ESMS cacld for C3,H28N402S2: 552.2; Found: 553.2 (M+H).
S S \
S S
O O
N, N
H H
'H NMR (DMSO-d6): S 11.3 (s, 2H), 7.75 (d, J=6.0 Hz, 2H), 7.5-7.4 (m, 12 H);
6.9 (m, 2H); ESMS cacld for C27H24N402S4: 564.1; Found: 565.2 (M+H).
s s 'H NMR (300MHz, CDC13): 8 10.18-8.60 (m, 2H), 7.26-6.46 (m, 8H), 3.80-3.02(m, 6H), 3.00-2.80(m, 12H). 1.78-1.56(m, 2H). ESMS cacld(C23H30N402S2):486.19;
found: 487 (M+H).
I O O /
O
s s 'H NMR (300MHz, DMSO): S 10.90-10.81 (m, 2H), 7.50-7.21 (m, 10H), 3.78-3.36(m, 6H), 2.64-0.50(m, 1OH). ESMS cacld(C20H28N402S2): 456.17; found: 457 (M+H).
N", N
NNC" i Fl/ Il O
s CN
'H NMR (300MHz, CDC13): 8 10.00-9.71 (m, 2H), 7.72-7.21(m, 8H), 3.80-3.26(m, 6H). ESMS cacld(C20H16N602S2):436.08; found: 437 (M+H).
S
iJIJI~ ~ \ / II N
J:bllr 0 s 'H NMR (300MHz, CDC13): 6 10.60-9.41 (m, 2H), 7.15-6.23(m, 6H), 3.89-3.28(m, 6H), 3.76(S, 12H). ESMS cacld(C22H28N406S2):506.13; found:507 (M+H).
NON i I \
O~r 0 s s FI O /
/
'H NMR (300MHz, DMSO): 8 7.40-7.12 (m, 1OH), 3.70-2.80(m, 6H), 1.84-0.72(m, 16H). ESMS cacld(C26H34N402S2):498.21; found: 499 (M+H).
F
S
{I F
N" N
O
6-Ir S
'H NMR (300MHz, CDC13): 6 10.42-9.53 (m, 2H), 7.55-6.87(m, 8H), 3.99-3.28(m, 6H), ESMS cacld(C18HION4F202S2): 422.07; found: 423 (M+H).
O,N
N"'N
jLf p~N \
S NOZ
'H NMR (300MHz, DMSO): 6 12.08 (br. 2H), 8.27-7.24 (m, 8H), 3.70-3.15(m, 6H).
ESMS cacld(C18H16N6O6S2):476.06; found: 477 (M+H).
O/
s \o Nl 0 `N
FI O ) O S
'H NMR (300MHz, CDC13): 6 10.12-9.83 (m, 2H), 7.15-6.63(m, 6H), 3.99-2.91(m, 6H), ESMS cacld(C22H26N406S2):506.13; found: 507 (M+H).
s /~\ s 'H NMR (300MHz, DMSO): 6 11.12-10.54 (m, 2H), 8.27-7.18 (m, 10H), 4.26-3.72(m, 2H), 3.37-3.18(m, 2H). ESMS cacld(C17H,6N402S2):372.07; found: 371 (M-H).
I S NON "IN S
S ti H 5 'H NMR (300MHz, DMSO): 8 11.52 (br, 2H), 7.95-7.33(m, 1OH), 3.42-3.22(m, 6H), 2.48(m, 2H). ESMS cacld(C23H2ON402S4):512.05; found: 513 (M+H).
NN N
\ S N\H N/N S
S
'H NMR (300MHz, CDC13): 5 7.81-7.28(m, 8H), 3.82(s, 6H). ESMS
cacld(C22H18N402S4):498.03; found: 499 (M+H).
1H NMR (300MHz, CDC13): S 10.02-9.11 (m, 2H), 8.16-7.28(m, 8H), 3.99-3.08(m, 6H), 2.90-1.20(m, 2H). ESMS cacld(C23H24N406S2):516.11; found: 517 (M+H).
o S S 0 'H NMR (300MHz, DMSO): 6 7.99 (m, 8H), 8.16-7.28(m, 8H), 3.80-3.14(m, 6H), 1.80-1.21(m, 2H). ESMS cacld(C2IH2ON406S2):488.08; found: 487 (M-H).
OY
1H NMR (300MHz, CDC13): 8 10.82-10.55 (m, 2H), 7.91-7.29(m, 1OH), 3.64-S
3.11(m, 6H), 1.90-1.40(m, 2H). ESMS cacld(C,9H2ON402S2):400.19; found: 399 (M-H).
Example 12 - Compound (1) Enhances the Anti-Cancer Activity of Paclitaxel In Vivo General Procedure of In Vivo Anti-Tumor Study The in vivo anti-cancer enhancing effect of novel compounds was assessed in tumor bearing mice using the tumor growth inhibition assay. Tumor cells were implanted by injection of a tumor cell suspension subcutaneously in the flank of a mouse.
Treatment of the tumor with an experimental compound and Paclitaxel begun after the tumor had been established (volume was about 100 mm3). Animal then begun a multiple injection schedule where the compound and Paclitaxel were given by IV route of administration. Tumors were measured two times a week. During the course of this assay, animals were monitored daily for signs of toxicity including body weight loss.
PROCEDURE
A supplemented media was prepared from 50% DMEM/Dulbecco Modified Eagle Medium (High Glucose), 50% RPMI 1640, 10% FBS/Fetal Bovine Serum (Hybridoma Tested; Sterile Filtered), I% L-Glutamine, I% Penicillin-Streptomycin, I%
MEM Sodium Pyruvate and 1% MEM Non-Essential Amino Acids. FBS was obtained from Sigma Chemical Co. and other ingredients were obtained from Invitrogen Life Technologies, USA). The supplemental media was warmed to 37 C and 50 ml of media was added to a 175 cm2 tissue culture flask.
The cells used in the assay were MDA-435 Human Breast Carcinoma from the American Type Culture Collection. 1 vial of MDA-435 cells from the liquid nitrogen frozen cell stock was removed. The frozen vial of cells was immediately placed into a 37 C water bath and gently swirled until thawed. The freeze-vial was wiped with 70%
ethanol and cells were immediately pipetted into the 175 cm2 tissue culture flask containing supplemented media. The cells were incubated overnight and the media was removed and replaced with fresh supplemented media the next day. The flask was incubated until flask became about 90% confluent. This took anywhere from 5-7 days.
The flask was washed with 10 ml of sterile room temperature phosphate buffered saline (PBS). The cells were trypsinized by adding 5 ml of warmed Trypsin-EDTA
(Invitrogen) to the flask of cells. The cells were then incubated for 2-3 minutes at 37 C
until cells begun to detach from the surface of the flask. An equal volume of supplemented media (5 ml) was added to the flask. All the cells were collected into 50 ml tube, and centrifuged at 1000 RPM for 5 minutes at 20 C. The supernatant was aspirated and the cell pellet was resuspended in 10 ml of supplemented media and the cells were counted. 1-3 million cells/flask were seeded into 5-7 tissue culture flasks (175 cm2). Each flask contained 50 ml of supplemented media. The flasks were incubated until about 90%
confluent. The passaging of the cells was repeated until enough cells have been grown for tumor implantation.
The above procedure for trypsinizing and centrifuging the cells were followed.
The supernatant was aspirated and the cell pellet was resuspended in 10 ml of sterile PBS
and the cells were counted. The cells were centrifuged and then resuspended with appropriate volume of sterile PBS for injection of correct number of cells needed for 5 tumor implantation. In the case of MDA-435, 100 million cells were suspended with 2.0 ml of sterile PBS to a final concentration of 50 million cells/ml in order to inject 5 million cells in 0.1 ml/mouse.
Mice (CD-1 nu/nu) were obtained from Charles River Laboratories:
nomenclature: Crl:CD-1-nuBR, Age: 6-8 weeks. The mice were allowed to acclimate for 10 1 week prior to their being used in an experimental procedure.
Implantation of the MDA-43 5 tumor cell suspension took place into the corpus adiposum of the female CD-1 nu/nu mouse. This fat body is located in the ventral abdominal viscera of the mouse. Tumor cells were implanted subsutaneously into the fat body located in the right quadrant of the abdomen at the juncture of the os coxae (pelvic 15 bone) and the os femoris (femur). 5 million MDA-435 cells in 0.1 ml of sterile PBS were injected using 27 G (1/2 inch) needle. MDA-435 tumors developed 2-3 weeks after implantation.
Compound stock solutions were prepared by dissolving the compound in cell-culture-grade DMSO (dimethyl sulfoxide) at the desired concentration. This stock 20 solution in DMSO was sonicated in an ultrasonic water bath until all the powder dissolved.
The Formulation Solvent was prepared as follows: 20% of Cremophore RH40 (Polyoxyl 40 Hydrogenated Castor Oil obtained from BASF corp.) in water was prepared by first heating 100 % Cremophore RH40 in a water bath at 5 0-60 C until it liquefied 25 and became clear. 10 ml of the 100 % Cremophore RH40 aliquoted into a conical centrifuge tube containing 40 ml of sterile water (1:5 dilution of Cremophore RH40). The 20% Cremophore RH40 solution was reheated until it became clear again, and mixed by inverting the tube several times. This 20 % Cremophore RH40 solution was stored at room temperature, and was kept for up to 3 months.
30 Preparation of Dosing Solution for Compound Administration: The compound stock solution was diluted 1:10 with 20% Cremophore RH40: 1) 2.0 ml of 10 mg/ml dosing solution of Compound (1) was prepared by diluting 100 mg/ml Compound Stock solution with 1.8 ml of 20 % Cremophore RH40 water solution; and 2) a dosoing solution comprising 2.0 ml of 1 mg/ml of Paclitaxel (obtained from Sigma Chemical Co.) 35 and 5 mg/ml of Compound (1) was obtained by mixing 0.1 ml of Compound 1 DMSO
stock solution (50 mg/ml) and 0.1 ml of Paclitaxel DMSO stock solution (10 mg/ml) and diluting with 1.8 ml of 20 % Cremophore RH40 water solution. The final formulation for the dosing solution was 10% DMSO, 18% Cremophore RH40 and 72% water.
The Dosing Solution (Dosing Volume: 0.01 ml/gram = 10 ml/ kg) was injected intravenously into the mice bearing MDA-435 human breast tumor.
PROTOCOL
Group Compounds (Dose) .1 Vehicle Only 2 Paclitaxel (5 mg/kg) 3 Compound (1) (50 mg/kg) 4 Paclitaxel (5 mg/kg) + Compund (1) (25 mg/kg) 5 Paclitaxel (5 mg/kg) + Compound (1) (50 mg/kg) Dosing Schedule : 3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group RESULTS
Figure 1 shows the effects of Compound (1) on enhancing anti-tumor activity of Paclitaxel (Taxol). As can be seen from Figure 1, Compound (1) significantly enhanced anti-tumor activity of Paclitaxel on human breast tumor MDA-435 in nude mice.
Figure 2 shows the effects of Compound (1) and Paclitaxel on the body weight of nude mice bearing MDA-435 human breast tumor. As can be seen from Figure 2, Compound (1) significantly enhanced anti-tumor activity of Paclitaxel without increasing toxicity.
Example 13 - Compounds (1) and (2) Enhance the Anticancer Activity of Paclitaxel In Vivo I i I
H H
S S
Compound (2) The protocol described in Example 12 was used to test Compounds (1) and (2) for their ability to enhance the anti-cancer activity of paclitaxel in mice, except as modified as described below.
PROTOCOL
Group Compounds (Dose) 1 Vehicle Only 2 Paclitaxel (2 mg/kg) 3 Paclitaxel (5 mg/kg) 4 Compound (1) (80 mg/kg) 5 Compound (2) (80 mg/kg) 6 Paclitaxel (2 mg/kg) + Compound (1) (80 mg/kg) 7 Paclitaxel (5 mg/kg) + Compound (1) (80 mg/kg) 8 Paclitaxel (2 mg/kg) + Compound (2) (80 mg/kg) 9 Paclitaxel (5 mg/kg) + Compound (2) (80 mg/kg) Dosing Schedule : 3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group.
RESULTS
Group Average Tumor Volume (mm3) % Tumor Growth on Day 23 1 301.3 100 2 259.8 86 3 164.8 55 4 270.0 90 5 305.8 101 6 193.3 64 7 106.2 35 8 148.4 49 9 60.6 20 Compounds (1) and (2) significantly enhanced anti-tumor activity of Paclitaxel at both of 2 mg/kg and 5 mg/kg without increasing toxicity.
Example 14 - Compound (1) Enhances the Anticancer Activity of Paclitaxel In Vivo The protocol described in Example 12 was used to test Compound (1) for its ability to enhance the anti-cancer activity of paclitaxel in mice, except modified as described below.
PROTOCOL
Group Compounds (Dose) 1 Vehicle Only 2 Paclitaxel (10 mg/kg) 3 Compound (1) (50 mg/kg) 4 Paclitaxel (10 mg/kg) + Compound (1) (25 mg/kg) Dosing Schedule :
3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group RESULTS
Group Average Tumor Volume [mm3] % Tumor Growth Inhibition on Day 1 752.2 -2 105.4 86%
3 754.9 0 %
4 0.59 > 99.9 %
When 10 mg/kg of Paclitaxel was used, significant anti-tumor activity was observed.
However, after drug treatment (Day 1-20) terminated, the tumor started growing to become 105 mm3 volume on Day 43. On the other hand, average tumor volume after treatment of Paclitaxel (10 mg/kg) plus Compound (1) (25 mg/kg) was only 0.59 mm3 with more than 99.9 % tumor growth inhibition.
Examplel 5 - Compounds (3)-(5) Enhance the Anticancer Activity of Paclitaxel In Vivo CI CI
O O Y N N
H H
S S
Compound (3) O j 0 N N
N N/
H H
S S
Compound (4) N
H H
S S
Compound (5) The protocol described in Example 12 was used to test Compounds (3)-(5) for their ability to enhance the anti-cancer activity of paclitaxel in mice, except modified as described below.
PROTOCOL
Group Compounds (Dose) 1 Vehicle Only 2 Paclitaxel (5 mg/kg) 3 Paclitaxel (5 mg/kg) + Compound (3) (50 mg/kg) 4 Paclitaxel (5 mg/kg) + Compound (4) (100 mg/kg) 5 Paclitaxel (5 mg/kg) + Compound (5)(100 mg/kg) Dosing Schedule :
3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group RESULTS
Group Average % Tumor Growth Inhibition on Day 27 Compounds (3)-(5) demonstrated significant enhancing effects of Taxol anti-tumor 15 activity.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled 20 in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Rio is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group,'-SR19, -NHR19 or -OR19.
R11 is a lower alkyl group, a substituted lower alkyl group, an aryl group or a substituted aryl group.
R12 is -H, -OH, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, -O-C(O)-(lower alkyl), -O-C(O)-(substituted lower alkyl), -O-CH2-O-(lower alkyl) -S-CH2-O-(lower alkyl).
R13 is -H, -CH3, or, taken together with R14, -CH2-.
R14 is -H, -OH, lower alkoxy, -O-C(O)-(lower alkyl), substituted lower alkoxy, -O-C(O)-(substituted lower alkyl), -O-CH2-O-P(O)(OH)2, -O-CH2-O-(lower alkyl), -O-CH2-S-(lower alkyl) or, taken together with R20, a double bond.
R15 -H, lower acyl, lower alkyl, substituted lower alkyl, alkoxymethyl, alkthiomethyl, -OC(O)-O(lower alkyl), -OC(O)-O(substituted lower alkyl), -OC(O)-NH(lower alkyl) or -OC(O)-NH(substituted lower alkyl).
R16 is phenyl or substituted phenyl.
R17 is -H, lower acyl, substituted lower acyl, lower alkyl, substituted, lower alkyl, (lower alkoxy)methyl or (lower alkyl)thiomethyl.
R18 -H, -CH3 or, taken together with R17 and the carbon atoms to which R17 and R18 are bonded, a five or six membered a non-aromatic heterocyclic ring.
R19 is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group.
R20 is -H or a halogen.
R21 is -H, lower alkyl, substituted lower alkyl, lower acyl or substituted lower acyl.
Preferably, the variables in Structural Formulas (VIII) and (IX) are defined as follows: R10 is phenyl, tert-butoxy, -S-CH2-CH-(CH3)2, -S-CH(CH3)3, -S-(CH2)3CH3, -O-CH(CH3)3, -NH-CH(CH3)3, -CH=C(CH3)2 orpara-chlorophenyl;
R11 is phenyl, (CH3)2CHCH2-, -2-furanyl, cyclopropyl orpara-toluyl; R12 is -H, -5 OH, CH3CO- or -(CH2)2-N-morpholino; R13 is methyl, or, R13 and R14, taken together, are -CH2-;
R14 is -H, -CH2SCH3 or -CH2-O-P(O)(OH)2; R15 is CH3CO-;
R16 is phenyl; R17 -H, or, R17 and R18, taken together, are -0-CO-0-;
R18 is -H; R20 is -H or -F; and R21 is -H, -C(O)-CHBr-(CH2)13-CH3 or -C(O)-10 (CH2)14-CH3; -C(O)-CH2-CH(OH)-COOH, -C(O)-CH2-O-C(O)-CH2CH(NH2)-CONH2, -C(O)-CH2-O--CH2CH2OCH3 or -C(O)-O-C(O)-CH2CH3.
A taxol analog can also be bonded to or be pendent from a pharmaceutically acceptable polymer, such as a polyacrylamide. One example of a polymer of this type is shown in Figure 26. The term "taxol analog", as it is used herein, includes 15 such polymers.
The disclosed compounds are enhancers of the anti-cancer activity of taxol and taxol analogs. A compound enhances the anti-cancer activity of taxol or a taxol analog when the activity of taxol or the taxol analog is greater when administered in combination with the compound than when administered alone. The degree of the increase in activity depends upon the amount of compound administered. The compounds of the present invention can therefore be used in combination with taxol or taxol analogs to treat subjects with cancers. Examples include colon cancer, pancreatic cancer, melanoma, renal cancer, sarcoma, breast cancer, ovarian cancer, lung cancer. stomach cancer, bladder cancer and cervical cancer.
A "subject" is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
In order to achieve an enhancement of the anti-cancer activity of taxol and taxol analogs, an effective amount of a compound of the present invention and an effective amount of taxol or analog of taxol are administered to the subject.
With respect to taxol or an analog of taxol, an "effective amount" is a quantity in which anti-cancer effects are normally achieved. With respect to a compound of the present invention, an "effective amount" is the quantity in which a greater anti-cancer effect is achieved when the compound is co-administered with taxol or a taxol analog compared with when taxol or the taxol analog is administered alone. The compound and taxol (or taxol analog) can be co-administered to the subject as part of the same pharmaceutical composition or, alternatively, as separate pharmaceutical compositions. When administered as separate pharmaceutical compositions, the compound or the present invention and taxol (or taxol analog) can be administered simultaneously or at different times, provided that the enhancing effect of the compound is retained.
The amount of compound and taxol (or taxol analog) administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of cancer.
The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for taxol and taxol analog are well known and typically range from between about 1 mg/mm2 per day and about 1000 mg/mm2 per day, preferably between about 10 mg/mm2 per day and about 500 mg/mm2 per day.
Effective amounts of a compound of the present invention typically range between about 1 mg/mm2 per day and about 10 grams/mm2 per day, and preferably between 10 mg/mm2 per day and about 5 grams/mm2.
The disclosed compounds are administered by any suitable route, including, for example, orally in capsules, suspensions or tablets or by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compounds can also be administered orally (e.g., dietary), topically, by inhalation (e.g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the type of cancer to be treated.
Oral or parenteral administration are preferred modes of administration. Suitable routes of administration of taxol and taxol analogs are well known in the art and include by parenteral administration, as described above for the compounds of the present invention. Suitable routes of administration for taxol and analogs thereof are well known and include inter alia parenteral and oral administration.
The disclosed compounds can be administered to the subject in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition for treatment of cancer. Formulation of the compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule).
Suitable pharmaceutical carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextrasn) are known in the art (Baker, et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).Suitable formulations for taxol and taxol analogs are well known in the art.
The disclosed compounds can be prepared according to methods described in Examples 1-12 and also according to methods described in U.S. Patent No.
6,825,235.
The present invention is illustrated by the following examples, which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1 S
S
S OH R1H2 N,NH2 NaOH / R' O R
R
Preparation of Thiobenzoic acid N-nnethylhydrazide: Thiobenzoic acid N-methylhydrazide were prepared in 88% yield by slight modification of the pricy art (Acta Chem. Scand. 1961, 1087-1096); 'H NMR (CDC13) 5 3.3, (s, 3H), 6:0 (s, 2H), 7.3-7.4 (m, 5H); ESMS calcd (C8H1oN2S): 166.1; found: 167.1 (M+H)+.
Example 2 Preparation of Thiobenzoic acid N-methyllnydrazide: Bromobenzene (1.6g, 10 mmol) was added into 25 ml anhydrous THE solution containing magnesium.
powder (0.3g, 12.5 mmol), and refluxed for 2 In. After it was cooled, the clear reaction solution was added into carbon disulfide (1 mi, 16.8 mmol) at 0 C, and stirred for 30 min at rt. The resulting mixture was then added into methylhydrazine (1.6 ml, 3Ommol) at 0 C, and stirred for another 2 hours. To this solution was added water (15 ml) and extracted with EtOAc (30 ml x 3). The organic solution was concentrated to minimum volume, and subjected to silica gel column chromatography (eluant: 1:3 - 1:1 ethyl acetate : hexanes) to give thiobenzoic acid N'-methyl hydrazide (0.72 g, total yield: 48 %). 'H NMR (CDC13) 8 3.3 (s, 3H), 6.0 (s, 2H), 7.3-7.4 (m, 5H); ESMS calcd (C8HION2S): 166.1; found: 167.1 (M+H)+.
Example 3 H RCOOH; DCC; DMAP (cat) R rO Lawesson's R / S
N 30. H3C' ,NH2 CH2C12 H3C'N=NH2 H3C'N.
0 C to RT
hiobenzoic acid N-methylhydrazine: DCC (4.5 g, 21.8 Preparation of 2,5-Dimethoxyt mmol) was added in one portion to a solution of 2,5-dimethoxybenzoic acid (3.6g, mol), methylhydrazine (1.2 ml, 23 mmol) and DMAP (30 mg, cat.) in CH2CI2 (60 ml) cooled in an ice bath. The reaction mixture was stirred overnight at room 15 temperature. The slurry was cooled at -20 C for 1 h and filtered. The solution was evaporated and the residue was dried in vacuum. The resulting crude product was dissolved in toluene (50 ml). To this solution was added Lawesson's reagent (5.8 g, 14 mmol). The mixture was refluxed for 40 min, cooled to room temperature, and directly subjected to silica gel column chromatography (eluent: 25 20 % to 35 % ethyl acetate in hexanes) to give the 2,5-dimethoxythiobenzoic acid N-methylhydrazide (3.7 g, yield: 82%) as off-white solid. 1H NMR (300MHz, CDCl3):
b 6.88-6.80(m, 3H), 5.46 (s, 2H), 3.84(s, 3H), 3.82 (s, 3H), 3.28(s, 3H).
Example 4 S HO R3 R2 off DCC, DMF R. , N R3 R2 N.
R~N'NH2 + R N N R Y's-R1 0 0 Method A RI 0 0 R1 Preparation ofN-Malonyl-bis[N'-methyl-N'-(thiobenzoyl)hydrazidel: To a stirred solution of thiobenzoic acid N-methylhydrazide (0.166 g, 10 mmol), HOBt'H20 (0.15 g, 11 mmol) and malonic acid (0.052 g, 5 mmol) in DMF (2 mL) was added DCC (0.22 g, 10.7 mmol) at 0 C. The resultant suspension was stirred at 0 C
for 1 h and at room temperature for 3 h. Precipitated material was filtered off and washed with EtOAc (3 x 15 mL). Combined filtrate and washings was washed successively with H2O (2 x 20 mL), 5% citric acid (20 mL),H20 (20 mL), Saturated NaHCO3 (20 mL) and brine (20 mL). After being dried over Na2SO4, the solvent was removed under reduced pressure to afford the crude product as a yellow solid, which was washed with warm EtOAc. 0.16 g (yield 80%) of pure product was obtained as a yellow powder. Rf 0.3 (Hexane/EtOAc 1:1 vlv); 1H NMR (CDC13) S 3.1 - 3.8 (m, 6H), 3.4 (s, 2H), 7.1- 7.45 (m, 10 H), 9.5 - 10.5 (m, 1 H) ppm; ESMS caled (C19H2ON402S2): 400.1; found: 399.1 (M-H)+.
Preparation of N-(2-Meth llmalonyl-bis {N'-methyl-N'-[(2,5-dimethoxy)thiobenzoyllhydrazidel :
O S H H S 'O
N.N N , .
,O ~'O
DCC (4 g, 19 mmol) was added to a solution of 2,5-dimethoxythiobenzoic acid N-methylhydrazide (3.7 g, 16.4 mmol) and 2-methylmalonic acid (2 g, 17 mmol) in DMF
(20 ml) with stirring at 0 C. The reaction mixture was stirred for lh at room temperature.
The slurry was cooled at -20 C for 1 h and filtered. The filtrate was diluted with EtOAc (300 ml), washed with water (50 ml x 3), dried with Na2SO4. The EtOAc solution was concentrated to minimum volume, and subjected to silica gel column chromatography (eluent: 1:4 to 2:1, ethyl acetate: hexanes) to give the title compound (3.5 g, 80 %) as yellow powder. 'H NMR (CDC13) 6 10.12-9.14 (214), 7.12-6.81 (m, 6H), 4.01-3.78(m, 6H), 3.75-3.22(m, 6H), 2.82-2.62(m, 1H), 1.12-0.11(m,3H); ESMS cacld (C24H30N406S2):534.16; found: 535.1 (M+H).
Example 5 CI~CISI RH 3 R2 H S
RN,NH2 0 O RJ~N,N\2/N,N1~1 R
R, R1 0 0 R, Preparation of N-Malonyl-bisfN'-methyj-N'-(thiobenzoyl)hydrazidel: To a solution of thiobenzoic acid N-methylhydrazine (10 g) stirred at 0 C were added subsequently triethylamine (8.5 mL) and malonyl dichloride (3.05 mL). The reaction mixture was stirred for 10 min, washed with water (3x50 mL), dried over sodium sulfate and concentrated. Purification by recrystallization from methylene dichloride (35 mL) gave the product as light yellow crystals (9.0 g, 75%) which was identical to the product 5 obtained in Example 6.
Example 6 S PhO\ K /OPh S R3 R2 S
RNNH2 O O R kN,N N,NR yNr R1 Method B R, 0 0 R1 Preparation of N-Malonyl-bis[N'-methyl-N'-(thiobenzoyl)hydrazidel: A stirred solution of thiobenzoic acid N-methylhydrazide (1.66 g, 10 mmol) and diphenyl malonate (1.30 g, 5.08 mmol) in dry THE (100 mL) was heated to reflux for 72 h. Volatile components were then removed under reduced pressure. The crude product was purified by column chromatography on silica gel using a mixture of hexane and EtOAc as eluant (gradient from 4:1 v/v to 1: 1 v/v). 1.07 g (51% yield) of pure product N-malonyl-bis[N'-methyl-N'-(thiobenzoyl)hydrazide] was obtained as a yellow powder. Physical property was identical to that obtained in Example 5.
Example 7 S
NH DCC, DMF 0--ir O O
N 2 0 0 N,N~ULO
S H
H OX~O
0' 1) TFA
2) DCC, DMF 0--r N'N-kIANA
S S H H g 0, 'O N.NH2 A slurry of thiobenzoic acid N-methylhydrazide (1.0 g, 6 mmol), mono-tert-butyl malonate (1.0 mL, 6 mmol), HOBt.H20 (0.98 g, 7.2 mmol), and DCC (1.34 g, 6.5 mmol) in DMF (5 mL) was stirred at 0 C for 3 h and then at room temperature for 3h.
Precipitated material was filtered off and washed with EtOAc (3 x 20 mL).
Combined filtrate and washings was washed successively with H2O (2 x 20 mL), 5% citric acid (20 mL), H2O (20 mL), Saturated NaHCO3 (20 mL) and brine (20 mL). After being -dried over Na2SO4, the solvent was removed under reduced pressure to afford the crude product as a solid, which was washed with Et2O. 0.94 g (yield 51 %) of pure product N'-Methyl-N'-thiobenzoyl-hydrazinocarbonyl)-acetic acid text-butyl ester was obtained as a yellow powder. 1H NMR (CDC13) S 1.6-1.7 (ds, 9H), 3.1-4.1 (m, 5 H), 7.3-7.7 (m, 5H), 9.7-10.3 (ds, 1H)ppm; ESMS calcd (C15H2ON203S): 308; found: 307 (M-H)+.
A solution of N'-methyl-N'-thiobenzoyl-hydrazinocarbonyl)-acetic acid tert-butyl ester (0.19g, 0.6 mmol) and TFA (0.12 mL, 1.6 mmol) in dry DCM (10 mL) was stirred at 10 C - 15 C for 12 h (reaction was monitored by TLC). Volatile components were removed under reduced pressure (bath temperature below 5 C). After being dried in vacuo, DMF (3 mL) was added followed by the addition of DCC (0.13 g, 0.6 mmol), HOBt'H20 (93 mg, 0.7 mmol) and thio-2,5-dimethoxybenzoic acid N-methylhydrazide (0.13 g, 0.57 mmol). The resultant solution was stirred at 0 C for half an hour and then at room temperature for 3h. Precipitated material was filtered off and washed with EtOAc (3 x 10 mL). Combined filtrate and washings was washed successively with (2 x 10 mL), 5% citric acid (10 mL), H2O (10 mL), Saturated NaHCO3 (20 mL) and brine (20 mL). After being dried over Na2SO4, the solvent was removed under reduced pressure to afford the crude product as an oil, which was purified by SGC (4:1 hexane/EA to 2:1 EtOAc/Hexane). 0.14 g (yield 53%) of pure product was obtained as a yellow powder. 'H NMR (CDC13) 6 3.1-3.9 (m, 18H), 6.7-7.4 (m, 9H)ppm; ESMS
calcd (C21H24N404S2): 460.1; found: 461.1 (M+H)+.
Example 8 o O
H EtOOEt H 0 0 H
N,NH2 N N
N N-R Xylene, reflux H H
1. anhydride R2 S S R2 )t,_A
2. Na2S; HCI H H N t Preparation of N- N-malonyl-bislN'-phenyl-N'-(thiobenzoyl)hydrazidel a/N, )LN N
H H
A mixture of phenylhydrazine (30 mL) and ethyl malonate (in xylene (150 mL) was heated to reflux overnight. The reaction was cooled to room temperature. The precipitates were collected via filtration and washed with ethanol to give N-malonyl-bis(N'-phenylhydrazide) as a white solid (14 g). The hydrazide (3.4 g) was suspended in benzoic anhydride (50 g) with warming. To it was added dropwise perchloric acid (57%
in water, 3 mL). The reaction mixture turned to clear solution initially and then quickly solidified. After standing at room temperature for 1 h, ether (50 mL) was added. The resulting slurry was filtered and washed with ether (2 x 00 mL) to give the perchlorate salts as a white solid (5.7 g). The salts were taken into acetone and added as a slurry over 5 min to Na2S (0.6 M in water, 90 mL) stirred at room temperature. After 30 min, the reaction was acidified with HC1(c) to afford a yellow slurry. The solid was collected via filtration and washed with water (20 mL) and ether (2x25 mL) to give N-malonyl-bis[N'-phenyl-N'-(thiobenzoyl)hydrazide] as an off-white solid (3.6 g). 1H NMR
(CDC13): b 7.2 (m, 20H); 3.5 (br s, 2H). MS calcd for C29H24N402S2: 524.13: Found: 525.1 (M+H).
Example 9 S H R3 R2 H S MeOH, DEAD SI~ R3 R2 S
RAN,N~N,NAR RJ)N'N s N,NAR
R1 0 0 R, R, 0 0 R, Preparation of N-Malonyl-bis[N-methyl-N'-phenyl-N'-(thiobenzoyl)hydrazidel To a stirred solution of N-malonyl-bis[N'-phenyl-N'-(thiobenzoyl)hydrazide]
(180 mg, 0.34 mmol), MeOH (22 uL) and triphenylphosphine (200 mg, 0.64 mmol) in dry THF(10 mL) was added a solution of DEAD (0.12 mL) in THE (3 mL) dropwise.
The resultant orange solution was stirred at room temperature for 12 h. After removal of the volatile components, the crude product was purified by SGC (3:1 Hexane/EtOAc) to afford 98 mg (52% yield) of the title compound as syrup. 'H NMR (CDC13) S 3.3-4.5 (m, 8H), 7.1-7.8 (m, 20 H)ppm; ESMS calcd (C31H28N402S2): 552; found: 551 (M-H)+.
Example 10 O O i l Lawessen's Reagent N PhH, reflux, lh 0-r N NA,,,~LH S
S H S S
N.N,,JLN.N
S H H S
A stirred mixture of N-malonyl-bis[N'-phenyl-N'-(thioacetyl)hydrazide) starting material (0.1 g, 0.25 mmol) and Lawesson's reagent (0.15 g, 0.37 mmol) in dry benzene (20 mL) was heated to reflux for 1 h. After being cooled to room temperature, the mixture was filtered through a layer of silica gel, washed with THE (2 x 15 mL). The filtrate and washings were combined and concentrated under reduced pressure.
Flush column chromatography on silica gel (hexane to 4:1 hexane/EtOAc to 2:1 hexane/EtOAc) afforded N-bisthiomalonyl-bis[N'-phenyl-N'-(thioacetyl)hydrazide as a clear syrup (16 mg, 15%). 'H NMR (CDCl3) 6 3.80-3.95 (m, 8H), 7.02-7.30 9m, 10 H).
ESMS calcd (C,9H2QN4S4): 432.06; found: 433.0 (M+H)+.
Example 11 The compounds shown below were prepared by the procedures described above.
Analytical data is provided for these compounds.
S S
NN NON
o 0 1 1, IH NMR (CDC13) 8 3.1- 3.8 (m, 6H), 3.4 (s, 2H), 7.1- 7.45 (m, 10 H), 9.5 -10.5 (m, 1H) ppm; ESMS calcd (CI9H2ON402S2): 400.1; found: 399.1 (M-H)+.
S H H S
N'NN,N
'HNMR (CDC13) 8 1.0-1.35 (m, 6H), 3.0-4.3 (m, 6H), 7.05-7.40 (m, 1OH), 9.1-10.1 (m, 2H); ESMS cacld (C21H24N4O2S2): 428.8; found: 427 (M-H)+. Anal Cale For C21H24N402S2 (428.13) C, 58.85; H, 5.64; N, 13.07; S, 14.96. Found: C, 58.73;
H, 5.62;
N, 12.97; S, 14.96.
Qinic H H N,N N,N 20 'H NMR (CDCl3) 8 0.7-1.0 (m, 6H), 1.4-1.9 (m, 4H), 3.1-4.2 (m, 6H), 7.1-7.4 (m, 1OH), 8.9-10.2 (m, 2H) ppm; ESMS (C23H28N402S2): 456.1; found: 455.1 (M-H)+.
S H H S
N.N N-N
O
mp 141 - 143 C; 'H NMR (CDC13) 8 0.6-1.05 (m, 6H), 1.1-1.9 (m, 8H), 3.0-4.2 (m, 6H), 7.0-7.35 (m, 1OH), 8.9-11 (ms, 2H). ESMS (C25H32N402S2): 484.2; found:
483.1 (M-H)+. Anal Cale For C25H32N402S2 (484.2) C, 61.95; H, 6.65; N, 11.56; S, 13.23.
Found: C, 61.98; H, 6.52; N, 11.26; S, 13.16.
S H I H S
N,N\~N,N
\N
'H NMR (DMSO-d6) S 0.4-0.9 (dd, 3H, J = 7), 2.7 (q, 1H), 3.1 - 3.6 (m, 6H), 7.1 - 7.5 (m, 1OH), 10.9 (br, 2H)ppm; ESMS (C20H22N402S2): 414; found: 413 (M-H)+.
S H H S
\ N.N N,N
'~y 'H NMR (CDC13) 6 0.5 (t, 3H, J= 7), 1.1-1.6 (m, 2H), 2.7 (t, 1H, J=7),3.1-3.3 (m, 6H), 7.0-7.3 (m, 1OH), 10.25 (s, 2H)ppm; MS (C21H24N402S2): 428.1; found:
427.1 (M-H)+.
S H H S
el N,N ;ry N=N 15 0 0 1H NMR (CDC13) 6 0.5 (d, 6H, J =7), 0.9-1.2 (m, 1H), 3.0-41 (m, 7H), 7.1-7.4(m, l OH), 10.3 (s, 2H)ppm; ESMS (C22H26N402S2): 442.1; found: 441.1 (M-H)+.
S H H S
N,N N.,N \
~~ I 0 0 ~~
'H NMR (CDC13) 6 0.4-1.3 (m, 5H), 1.5-1.8 (m, 2H), 3.0-3.7 (m, 6H), 7.1-7.5 (m, 10H), 11 (s, 2H) ppm; ESMS (C23H28N402S2): 456.1; found: 455.1 (M-H)+.
S S
H H
{N0 N N,N
I O O I
'H NMR (CDC13) 6 2.1 (d, 2H, J =7), 2.9 (t, 1H, J =7), 3.1-3.5 (m, 6H), 6.8-7.4 (m, 15 H), 11 (s, 2H)ppm; ESMS (C26H26N4O2S2): 490.1; found: 489.1 (M-H)+.
S H ll H S
N'NN,N
o rr0II
'H NMR (CDC13) 8 0.4 (d, 3H, J = 7), 1.0-1.4 (m, 6H), 2.75 (q, 1H), 3.0-4.3 (m, 4H), 7.1-7.4 (m, IOH), 10.6 (s, 2H); ESMS Calc For (C22H26N402S2): 442.1; found:
441.1 (M-H)+; Anal Calc For C22H26N402S2 (442.15) C, 59.70; H, 5.92; N, 12.66; S, 14.49. Found:
C, 59.64; H, 5.92; N, 12.59; S, 14.47.
S H H S
N'N N.N
~ I
\ I
'H NMR (DMSO-d6) S 3.20 (br, 2H), 7.1-7.6 (m, 20 H), 11.5 (s, 2H) ppm; ESMS
calcd (C29H24N402S2): 524.1; found: 523.1 (M-H)+.
S H H S
\ N'N(N'N
~O / I ~III IIOII I
'H NMR (CDC13) 8 3.0-4.3 (m, 14H), 6.6-7.5 (m, 8H), 10.4 (s, 211) ppm; ESMS
calcd (C2 1 H24N4O2 S 2) : 460.2; found: 461.2 (M+H)+.
S H H S
\ N.N~N.N \
Cl I I O O I CI
'H NMR (CDC13) 6 2.65-3.60 (in, 8H), 7.2-7.4 (m, 8H), 11.1 (br, 2H); ESMS
calcd (C19H18C12N4O2S2): 468.0; found: 467.9 (M-H)+.
S H H S
el N'N N,N 25 0 0 1 'H NMR (CDC13) S 0.4 (d, 3H, J = 7), 2.7 (q, 1H, J = 7), 3.0-3.8 (m, 6H), 7.2-8.2 (m, 8H), 10.5-10.7 (ms, 2H) ppm; ESMS calcd (C20H2OC12N402S2): 482.0; found: 481.0 (M-H)+.
s H H S
WN`^/N.N
O O I
'H NMR (CDC13) 6 2.9-3.8 (m, 6H), 7.3-7.7 (m, 4H), 8.0-8.3 (m, 4H), 10.9 (s, 2H);
ESMS calcd (C10H18N606S2): 490.0; found: 489.0 (M-H)+.
S H H S
I ~
eo N,NN,N
/
O O O b 'H NMR (CDC13) S 3.1-3.9 (m, 14H), 6.7-7.8 (m, 8H), 9.0-10 (m, 2H) ppm; ESMS
calcd (C21H24N404S2): 460.1; found: 459.1 (M-H)+.
S H H S
O~1 i0 (SBR-11-5032): 'H NMR (CDC13) 6 3.0-3.9 (m, 14H), 6.7-7.3 (m, 8H), 9.0-10 (m, 2H) ppm; ESMS calcd (C21H24N404S2): 460.1; found: 459.1 (M-H)+.
S H H S
c N,N N.N O Iry 20 o o 111 /
'H NMR (acetone-d6) 6 3.5 (s, 2H), 6.45 (d, 2H, J = 5), 6.9 (d, 2H, J = 5), 7.2-7.6 (m, 12H), 10.6 (s, 2H) ppm; ESMS calod (C25H2ON404S2): 504.1; found: 503.1 (M-H)+.
CI S H H. S CI
N, {1 N
Np O O l pN
'H NMR (DMSO-d6) S 2.60 (s, 6H), 3.05 (s, 6H), 3.40 (s, 2H), 7.15-7.50 (m, 8H)ppm;
ESMS calcd (C27H24C12N604S2): 630.1; found: 629.1 (M-H)+.
N=NrN=N 1`110 ~,O -0 'H NMR (CDC13) 8 10.06-8.82 (2H), 7.16-6.81(m,6H), 4.01-3.81(m, 6H), 3.78-3.11(m,6H), 2.81-2.58(m,2H): ESMS cacld (C23H28N406S2): 520.15; found: 521 (M+H).
"1 0 S H H S 0 ~10i N,N N.N O"
0 0 'H NMR (CDC13) S 10.38-9.01 (2H), 7.12-6.82 (m, 6H), 3.92-3.78(m, 12H), 3.75-3.06(m, 6H), 2.61-2.51 (m, 2H); ESMS caccd (C23H28N406S2): 520.15; found: 521 (M+H).
1~ O S H H S 1-1 O
"0 N.N N-N 0"
'H NMR (CDC13) 3 9.45-8.63 (2H), 7.18-6.81 (m, 6H), 4.01-3.80(m, 6H), 3.78-3.24(m, 6H), 2.62-2.50(m, IH), 1.74-0.11 (m, 3H); ESMS caccd (C24H3oN406S2):534.16;
found:
535 (M+H).
S H H S
N r,,~,N.N O O
'H NMR (CDC13) S 10.19-8.61 (2H), 7.26-6.52(m, 6H), 3.81-3.08(m, 8H), 3.01-2.88(m, 12H). ESMS cacld (C23H30N602S2): 486.19; found: 487 (M+H).
O S H H S "1 O
N~~N.
N" N
Cl CI
'H NMR (CDCl3) 8 9.92-8.80 (2H), 7.41-6.72 (m, 6H), 4.01-3.81(m,6H), 3.80-3.15 (m,6H), 2.76-2.42(m, 2H); ESMS cacld (C21H22C12N404S2):528.05; found:
529(M+H).
O S H H S
N.N N.N
O O CI CI
'H NMR (CDC13) 8 10.21-9.02(2H), 7.60-6.81 (m, 6H), 4.14-3.88(m, 6H), 3.87-3.18 (m,6H), 2.84-2.65(m, 1H),1.10-0.16 (m, 3H); ESMS cacld (C22H24C12N404S2):
542.06;
found: 543(M+H).
F S H H S F
N.N N.N
O O ~
F F
'H NMR (CDC13) 6 10.02-9.20 (2H), 7.63-7.01 (m, 6H), 4.21-3.22(m, 6H), 1.88-1.36 (m, 2H); ESMS cacid (C19Hi6F4N402S2): 472.07; found: 473 (M+H).
F S H H S F
NN NN
O
F F
1H NMR (CDCl3) 6 7.93-7.61 (2H), 7.40-6.92 (m, 6H), 3.98-3.41 (m, 6H), 2.19-0.93 (m, 4H); ESMS cacld (C20H,8F4N402S2): 486.08; found: 487 (M+H).
Cl S H H S Cl N.N N.N
O O
CI CI
'H NMR (CDC13) 6 10.12-9.21(2H), 7.67-7.23 (m, 6H), 3.94-3.22 (m, 6H), 2.01-1.21 (m, 2H); ESMS cacld (C,9H16C14N402S2): 535.95; found: 537(M+H).
Cl S H H S Cl N.N NN
O O l CI CI
'H NMR (CDC13) 6 7.78-7.23 (2H),'4.56-3.10 (m, 6H), 2.34-1.12 (m, 4H); ESMS
cacld (C20H1 sC14N402S2): 549.96; found: 551 (M+H).
O S H H S "O
1 11 N.N N.N
l O O O O b I
1H NMR (CDCI3) S 9.92-9.01 (2H), 7.38-7.15 (m,3H), 6.66-6.51 (m,3H), 3.98-3.75 (m,12H), 3.72-3.21(m,6H), 2.01-0.42 (m, 4H); ESMS cacld (C24H3oN406S2):534.16;
found: 535 (M+H).
S H H S
N.N r,-,YN.N
l 'H NMR (CDC13) S 10.51-9.82 (2H), 7.42-6.80 (m, 6H), 3.92-3.04(m, 6H), 2.60-1.21 (m, 14H); ESMS cacld (C23H28N402S2): 456.17; found: 457(M+H).
S H H S
NN N.N
'HNMR (CDC13) S 10.51-8.82 (2H), 7.11-6.89 (m, 6H), 3.81-3.02,(m, 6H), 2.40-1.02 (m, 16H); ESMS cacld (C24H3oN402S2): 470.18; found: 471(M+H).
O S H H S "0 N N~~N.N
J O O J i 'HNMR (CDC13) 8 9.86-8.42 (2H), 7.01-6.6 (m, 6H), 4.18-3.51 (m, 16H), 3.22-2.26 (2H), 1.40-1.04 (m, 6H); ESMS cacld (C25H32N406S2):548.18; found: 547 (M-H).
0 S H H S. O
N,NYcN.N
I~ J J 0 of I~
~O '10 'HNMR (CDC13) 6 9.99-8.41 (2H), 7.01-6.68 (m, 6H), 4.18-3.56 (m, 16H), 1.40-0.02 (m, 1OH); ESMS cacld (C26H34N406S2): 562.19; found: 561(M-H).
N.NN.N
'HNMR (CDC13) 6 10.12-8.82 (2H), 7.03-6.62 (m, 6H), 4.21-3.87 (m, 8H), 3.84-3.01(m, 6H), 2.71-2.42 (m, 2H), 1.56-1.21 (m, 12H); ESMS cacld (C27H36N406S2): 576.21;
found: 577(M+H).
N'N N=N 11-cr 1 0 0 1 i 1H NMR (CDC13) 6 9.81-8.79 (2H), 7.01-6.64 (m, 6H), 4.21-3.81(m, 8H), 3.80-3.22 (m, 6H), 1.54-1.20 (m, 13H), 1.01-0.16 (m, 3H); ESMS cacid (C28H38N406S2): 590.22;
5 found: 591(M+H).
S S
a O O
/N.NIN.N
H H
1H NMR (DMSO-d6): 6 8.25 (d, J=8.1 Hz, 4H), 7.50 (d, J=8.1 Hz, 4H), 3.7-3.3 (m, 8H);
10 ESMS cacid for C19H18N606S2: 490.1; Found: 489.0 (M-H).
NC CN
, I S S
O O
N.Nfil-A N'N
H H
'H NMR (CDC13): 5-10.25 (m, 2H), 7.7-7.4 (m, 8H), 3.7 (m, 2H), 3.35 (m, 61H);
ESMS
cacid for C21H18N602S2: 450.1; Found: 449.0 (M-H).
N N
~- I S S
N.NfilA N=N
H H
1H NMR (CDC13): 8 8.2 (s, 2H), 7.7-7.5 (m, 4H), 3.7-3.4 (m, 8H), 2.9-2.8 (m, 6H);
ESMS cacid for C19H22N602S2: 430.1; Found: 431.1 (M+H).
CN CN
6 S S ~
N.NIN.N,,,~
H H
'H NMR (CDC13): 6 10.0-9.2 (m, 2H), 7.9-7.45 (m, 8H), 4.0-3.4 (m, 8H); ESMS
cacld for C21H18N602S2: 450.1; Found: 451.0 (M+H).
F F
N'N1N'NI--, H H
'H NMR (CDC13): 6 10.1-9.4 (2H), 7.5-7.2 (m, 8H), 3.9-3.3 (m, 8H); ESMS cacld for C 14H18F2N402S2: 436.1; Found: 437.1 (M+H).
N\ // n \
'H NMR (CDC13): 6 3.3 (s, 2H), 3.6 (s, 6H), 5.25 (s, 4H), 7.05-7.3 (m, 16H), 7.6 (s, 2H), 7.9 (d, 2H, J = 6), 10.56 (s, 2H)ppm; ESMS calcd (C37H34N602S2): 658.2; found:
659.2 (M+H)+.
s N 0 H/
I
0 s 1H NMR (DMSO) 6 11.98 (2H), 7.44-7.12 (m, 10H), 3.69-3.14(s, 6H). ESMS cacld (C18H18N402S2): 386.09: found: 387.1 (M+H).
o H"r~. I
o 'H NMR (CHC13) 6 9.48-8.55 (2H), 7.56-7.20(m, 10H), 3.80-3.31(m, 6H), 2.88-2.22(m, 4H). ESMS cacld (C20H22N402S2): 414.12; found: 415.1 (M+H).
S S -(D~N-NH HN-N
O
IH NMR (300 MHz, CDC13) 6 10.21-9.91 (m, 2H), 8.06-7.32 (m, 14H), 3.91-3.56 (m, 6H). ESMS cacld (C24H22N402S2): 462.12; found: 463 (M+H).
S
Crj',N - N H
S
O
HN-N
'H NMR (300 MHz, DMSO-d6) 6 11.60-11.40 (m, 2H), 7.48-6.46 (m, 12H), 3.64-3.3.30(m, 6H). ESMS cacld (C20H2ON402S2): 412.10; found: 413 (M+H).
S
NN~\
O N N
S
'HNMR (300 MHz, CDC13) 6 7.58-7.20 (m, 12H), 3.68-3.20 (m, 6H). ESMS cacld (C20H2ON402S2): 412.10; found: 413 (M+H).
S
N-N\
S O
NN
'H NMR (300 MHz, CDC13): S 9.65-8.70 (2H), 8.01-7.21(m, 14H), 3.84-3.40(in, 6H).
ESMS cacld (C24H22N402S2): 462.12: found: 463 (M+H).
Orsoos1.O
N)1'-A \~H HN ~/
'H NMR (CDC13): 6 7.2 (m, 18H); 3.5 (br s, 2H); 2.4 (br s, 6H). MS calcd for C31 H28N402S2: 552.2: Found: 553.2 (M+H).
H3C--r O oy O O
I S S
O IOI
\ I N H~~H,N ~ i 1H NMR (CDC13): 8 7.5 (br s, 18H), 3.4 (br s, 2H), 2.45 (s, 6H). ESMS cacld for C33H28N406S2: 640.1; Found 641.1 (M+H).
: S S
/ II N,HAXAHN ( ~
1H NMR (CDC13-D20): 6 7.45-7.15 (m, 20 H), 1.6 (br s, 6H). ESMS cacld for C3,H28N402S2: 552.2; Found: 553.2 (M+H).
S S \
S S
O O
N, N
H H
'H NMR (DMSO-d6): S 11.3 (s, 2H), 7.75 (d, J=6.0 Hz, 2H), 7.5-7.4 (m, 12 H);
6.9 (m, 2H); ESMS cacld for C27H24N402S4: 564.1; Found: 565.2 (M+H).
s s 'H NMR (300MHz, CDC13): 8 10.18-8.60 (m, 2H), 7.26-6.46 (m, 8H), 3.80-3.02(m, 6H), 3.00-2.80(m, 12H). 1.78-1.56(m, 2H). ESMS cacld(C23H30N402S2):486.19;
found: 487 (M+H).
I O O /
O
s s 'H NMR (300MHz, DMSO): S 10.90-10.81 (m, 2H), 7.50-7.21 (m, 10H), 3.78-3.36(m, 6H), 2.64-0.50(m, 1OH). ESMS cacld(C20H28N402S2): 456.17; found: 457 (M+H).
N", N
NNC" i Fl/ Il O
s CN
'H NMR (300MHz, CDC13): 8 10.00-9.71 (m, 2H), 7.72-7.21(m, 8H), 3.80-3.26(m, 6H). ESMS cacld(C20H16N602S2):436.08; found: 437 (M+H).
S
iJIJI~ ~ \ / II N
J:bllr 0 s 'H NMR (300MHz, CDC13): 6 10.60-9.41 (m, 2H), 7.15-6.23(m, 6H), 3.89-3.28(m, 6H), 3.76(S, 12H). ESMS cacld(C22H28N406S2):506.13; found:507 (M+H).
NON i I \
O~r 0 s s FI O /
/
'H NMR (300MHz, DMSO): 8 7.40-7.12 (m, 1OH), 3.70-2.80(m, 6H), 1.84-0.72(m, 16H). ESMS cacld(C26H34N402S2):498.21; found: 499 (M+H).
F
S
{I F
N" N
O
6-Ir S
'H NMR (300MHz, CDC13): 6 10.42-9.53 (m, 2H), 7.55-6.87(m, 8H), 3.99-3.28(m, 6H), ESMS cacld(C18HION4F202S2): 422.07; found: 423 (M+H).
O,N
N"'N
jLf p~N \
S NOZ
'H NMR (300MHz, DMSO): 6 12.08 (br. 2H), 8.27-7.24 (m, 8H), 3.70-3.15(m, 6H).
ESMS cacld(C18H16N6O6S2):476.06; found: 477 (M+H).
O/
s \o Nl 0 `N
FI O ) O S
'H NMR (300MHz, CDC13): 6 10.12-9.83 (m, 2H), 7.15-6.63(m, 6H), 3.99-2.91(m, 6H), ESMS cacld(C22H26N406S2):506.13; found: 507 (M+H).
s /~\ s 'H NMR (300MHz, DMSO): 6 11.12-10.54 (m, 2H), 8.27-7.18 (m, 10H), 4.26-3.72(m, 2H), 3.37-3.18(m, 2H). ESMS cacld(C17H,6N402S2):372.07; found: 371 (M-H).
I S NON "IN S
S ti H 5 'H NMR (300MHz, DMSO): 8 11.52 (br, 2H), 7.95-7.33(m, 1OH), 3.42-3.22(m, 6H), 2.48(m, 2H). ESMS cacld(C23H2ON402S4):512.05; found: 513 (M+H).
NN N
\ S N\H N/N S
S
'H NMR (300MHz, CDC13): 5 7.81-7.28(m, 8H), 3.82(s, 6H). ESMS
cacld(C22H18N402S4):498.03; found: 499 (M+H).
1H NMR (300MHz, CDC13): S 10.02-9.11 (m, 2H), 8.16-7.28(m, 8H), 3.99-3.08(m, 6H), 2.90-1.20(m, 2H). ESMS cacld(C23H24N406S2):516.11; found: 517 (M+H).
o S S 0 'H NMR (300MHz, DMSO): 6 7.99 (m, 8H), 8.16-7.28(m, 8H), 3.80-3.14(m, 6H), 1.80-1.21(m, 2H). ESMS cacld(C2IH2ON406S2):488.08; found: 487 (M-H).
OY
1H NMR (300MHz, CDC13): 8 10.82-10.55 (m, 2H), 7.91-7.29(m, 1OH), 3.64-S
3.11(m, 6H), 1.90-1.40(m, 2H). ESMS cacld(C,9H2ON402S2):400.19; found: 399 (M-H).
Example 12 - Compound (1) Enhances the Anti-Cancer Activity of Paclitaxel In Vivo General Procedure of In Vivo Anti-Tumor Study The in vivo anti-cancer enhancing effect of novel compounds was assessed in tumor bearing mice using the tumor growth inhibition assay. Tumor cells were implanted by injection of a tumor cell suspension subcutaneously in the flank of a mouse.
Treatment of the tumor with an experimental compound and Paclitaxel begun after the tumor had been established (volume was about 100 mm3). Animal then begun a multiple injection schedule where the compound and Paclitaxel were given by IV route of administration. Tumors were measured two times a week. During the course of this assay, animals were monitored daily for signs of toxicity including body weight loss.
PROCEDURE
A supplemented media was prepared from 50% DMEM/Dulbecco Modified Eagle Medium (High Glucose), 50% RPMI 1640, 10% FBS/Fetal Bovine Serum (Hybridoma Tested; Sterile Filtered), I% L-Glutamine, I% Penicillin-Streptomycin, I%
MEM Sodium Pyruvate and 1% MEM Non-Essential Amino Acids. FBS was obtained from Sigma Chemical Co. and other ingredients were obtained from Invitrogen Life Technologies, USA). The supplemental media was warmed to 37 C and 50 ml of media was added to a 175 cm2 tissue culture flask.
The cells used in the assay were MDA-435 Human Breast Carcinoma from the American Type Culture Collection. 1 vial of MDA-435 cells from the liquid nitrogen frozen cell stock was removed. The frozen vial of cells was immediately placed into a 37 C water bath and gently swirled until thawed. The freeze-vial was wiped with 70%
ethanol and cells were immediately pipetted into the 175 cm2 tissue culture flask containing supplemented media. The cells were incubated overnight and the media was removed and replaced with fresh supplemented media the next day. The flask was incubated until flask became about 90% confluent. This took anywhere from 5-7 days.
The flask was washed with 10 ml of sterile room temperature phosphate buffered saline (PBS). The cells were trypsinized by adding 5 ml of warmed Trypsin-EDTA
(Invitrogen) to the flask of cells. The cells were then incubated for 2-3 minutes at 37 C
until cells begun to detach from the surface of the flask. An equal volume of supplemented media (5 ml) was added to the flask. All the cells were collected into 50 ml tube, and centrifuged at 1000 RPM for 5 minutes at 20 C. The supernatant was aspirated and the cell pellet was resuspended in 10 ml of supplemented media and the cells were counted. 1-3 million cells/flask were seeded into 5-7 tissue culture flasks (175 cm2). Each flask contained 50 ml of supplemented media. The flasks were incubated until about 90%
confluent. The passaging of the cells was repeated until enough cells have been grown for tumor implantation.
The above procedure for trypsinizing and centrifuging the cells were followed.
The supernatant was aspirated and the cell pellet was resuspended in 10 ml of sterile PBS
and the cells were counted. The cells were centrifuged and then resuspended with appropriate volume of sterile PBS for injection of correct number of cells needed for 5 tumor implantation. In the case of MDA-435, 100 million cells were suspended with 2.0 ml of sterile PBS to a final concentration of 50 million cells/ml in order to inject 5 million cells in 0.1 ml/mouse.
Mice (CD-1 nu/nu) were obtained from Charles River Laboratories:
nomenclature: Crl:CD-1-nuBR, Age: 6-8 weeks. The mice were allowed to acclimate for 10 1 week prior to their being used in an experimental procedure.
Implantation of the MDA-43 5 tumor cell suspension took place into the corpus adiposum of the female CD-1 nu/nu mouse. This fat body is located in the ventral abdominal viscera of the mouse. Tumor cells were implanted subsutaneously into the fat body located in the right quadrant of the abdomen at the juncture of the os coxae (pelvic 15 bone) and the os femoris (femur). 5 million MDA-435 cells in 0.1 ml of sterile PBS were injected using 27 G (1/2 inch) needle. MDA-435 tumors developed 2-3 weeks after implantation.
Compound stock solutions were prepared by dissolving the compound in cell-culture-grade DMSO (dimethyl sulfoxide) at the desired concentration. This stock 20 solution in DMSO was sonicated in an ultrasonic water bath until all the powder dissolved.
The Formulation Solvent was prepared as follows: 20% of Cremophore RH40 (Polyoxyl 40 Hydrogenated Castor Oil obtained from BASF corp.) in water was prepared by first heating 100 % Cremophore RH40 in a water bath at 5 0-60 C until it liquefied 25 and became clear. 10 ml of the 100 % Cremophore RH40 aliquoted into a conical centrifuge tube containing 40 ml of sterile water (1:5 dilution of Cremophore RH40). The 20% Cremophore RH40 solution was reheated until it became clear again, and mixed by inverting the tube several times. This 20 % Cremophore RH40 solution was stored at room temperature, and was kept for up to 3 months.
30 Preparation of Dosing Solution for Compound Administration: The compound stock solution was diluted 1:10 with 20% Cremophore RH40: 1) 2.0 ml of 10 mg/ml dosing solution of Compound (1) was prepared by diluting 100 mg/ml Compound Stock solution with 1.8 ml of 20 % Cremophore RH40 water solution; and 2) a dosoing solution comprising 2.0 ml of 1 mg/ml of Paclitaxel (obtained from Sigma Chemical Co.) 35 and 5 mg/ml of Compound (1) was obtained by mixing 0.1 ml of Compound 1 DMSO
stock solution (50 mg/ml) and 0.1 ml of Paclitaxel DMSO stock solution (10 mg/ml) and diluting with 1.8 ml of 20 % Cremophore RH40 water solution. The final formulation for the dosing solution was 10% DMSO, 18% Cremophore RH40 and 72% water.
The Dosing Solution (Dosing Volume: 0.01 ml/gram = 10 ml/ kg) was injected intravenously into the mice bearing MDA-435 human breast tumor.
PROTOCOL
Group Compounds (Dose) .1 Vehicle Only 2 Paclitaxel (5 mg/kg) 3 Compound (1) (50 mg/kg) 4 Paclitaxel (5 mg/kg) + Compund (1) (25 mg/kg) 5 Paclitaxel (5 mg/kg) + Compound (1) (50 mg/kg) Dosing Schedule : 3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group RESULTS
Figure 1 shows the effects of Compound (1) on enhancing anti-tumor activity of Paclitaxel (Taxol). As can be seen from Figure 1, Compound (1) significantly enhanced anti-tumor activity of Paclitaxel on human breast tumor MDA-435 in nude mice.
Figure 2 shows the effects of Compound (1) and Paclitaxel on the body weight of nude mice bearing MDA-435 human breast tumor. As can be seen from Figure 2, Compound (1) significantly enhanced anti-tumor activity of Paclitaxel without increasing toxicity.
Example 13 - Compounds (1) and (2) Enhance the Anticancer Activity of Paclitaxel In Vivo I i I
H H
S S
Compound (2) The protocol described in Example 12 was used to test Compounds (1) and (2) for their ability to enhance the anti-cancer activity of paclitaxel in mice, except as modified as described below.
PROTOCOL
Group Compounds (Dose) 1 Vehicle Only 2 Paclitaxel (2 mg/kg) 3 Paclitaxel (5 mg/kg) 4 Compound (1) (80 mg/kg) 5 Compound (2) (80 mg/kg) 6 Paclitaxel (2 mg/kg) + Compound (1) (80 mg/kg) 7 Paclitaxel (5 mg/kg) + Compound (1) (80 mg/kg) 8 Paclitaxel (2 mg/kg) + Compound (2) (80 mg/kg) 9 Paclitaxel (5 mg/kg) + Compound (2) (80 mg/kg) Dosing Schedule : 3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group.
RESULTS
Group Average Tumor Volume (mm3) % Tumor Growth on Day 23 1 301.3 100 2 259.8 86 3 164.8 55 4 270.0 90 5 305.8 101 6 193.3 64 7 106.2 35 8 148.4 49 9 60.6 20 Compounds (1) and (2) significantly enhanced anti-tumor activity of Paclitaxel at both of 2 mg/kg and 5 mg/kg without increasing toxicity.
Example 14 - Compound (1) Enhances the Anticancer Activity of Paclitaxel In Vivo The protocol described in Example 12 was used to test Compound (1) for its ability to enhance the anti-cancer activity of paclitaxel in mice, except modified as described below.
PROTOCOL
Group Compounds (Dose) 1 Vehicle Only 2 Paclitaxel (10 mg/kg) 3 Compound (1) (50 mg/kg) 4 Paclitaxel (10 mg/kg) + Compound (1) (25 mg/kg) Dosing Schedule :
3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group RESULTS
Group Average Tumor Volume [mm3] % Tumor Growth Inhibition on Day 1 752.2 -2 105.4 86%
3 754.9 0 %
4 0.59 > 99.9 %
When 10 mg/kg of Paclitaxel was used, significant anti-tumor activity was observed.
However, after drug treatment (Day 1-20) terminated, the tumor started growing to become 105 mm3 volume on Day 43. On the other hand, average tumor volume after treatment of Paclitaxel (10 mg/kg) plus Compound (1) (25 mg/kg) was only 0.59 mm3 with more than 99.9 % tumor growth inhibition.
Examplel 5 - Compounds (3)-(5) Enhance the Anticancer Activity of Paclitaxel In Vivo CI CI
O O Y N N
H H
S S
Compound (3) O j 0 N N
N N/
H H
S S
Compound (4) N
H H
S S
Compound (5) The protocol described in Example 12 was used to test Compounds (3)-(5) for their ability to enhance the anti-cancer activity of paclitaxel in mice, except modified as described below.
PROTOCOL
Group Compounds (Dose) 1 Vehicle Only 2 Paclitaxel (5 mg/kg) 3 Paclitaxel (5 mg/kg) + Compound (3) (50 mg/kg) 4 Paclitaxel (5 mg/kg) + Compound (4) (100 mg/kg) 5 Paclitaxel (5 mg/kg) + Compound (5)(100 mg/kg) Dosing Schedule :
3 times a week (Monday, Wednesday, Friday) for 3 weeks 5 mice were used for each group RESULTS
Group Average % Tumor Growth Inhibition on Day 27 Compounds (3)-(5) demonstrated significant enhancing effects of Taxol anti-tumor 15 activity.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled 20 in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (37)
1. A compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R1 and R2 are independently an aryl group or a substituted aryl group;
R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group; and Z is =O or =S;
provided that when Y is -CH2-, R3 and R4 are both phenyl and R5-R6 are all -H, then R1 and R2 are not both phenyl.
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R1 and R2 are independently an aryl group or a substituted aryl group;
R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group; and Z is =O or =S;
provided that when Y is -CH2-, R3 and R4 are both phenyl and R5-R6 are all -H, then R1 and R2 are not both phenyl.
2. The compound of Claim 1 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8- and R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8- and R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
3. The compound of Claim 2 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y" is a covalent bond or -CH2-.
or a pharmaceutically acceptable salt thereof wherein Y" is a covalent bond or -CH2-.
4. The compound of Claim 2 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8-.
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8-.
5. The compound of Claim 4 wherein R1 and R2 are both aryl or substituted aryl groups and R3 and R4 are both a lower alkyl group or a substituted lower alkyl group.
6. The compound of Claim 5 wherein R1 and R2 are both phenyl or substituted phenyl and R3 and R4 are both methyl, ethyl, phenyl, or thienyl.
7. The compound of Claim 6 wherein R7 and R8 are both methyl or wherein R7 and R8, taken together, are propylene or butylenes, or R7 is -H and R8 is lower alkyl, thienyl, phenyl or benzyl.
8. A compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
9. The compound of Claim 8 wherein R1 and R2 are both phenyl optionally substituted with one or more groups selected from -OH, -Br, -Cl, -I, -F, -OR a, -O-COR a, -COR
a, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR a, -N(R a R b), -COOR a, -CHO, -CONH2, -CONHR a, -CON(R a R b), -NHCOR a, -NRCOR a, -NHCONH2, -NHCONR a H, -NHCON(R a R b), -NR c CONH2, -NR c CONR a H, -NR c CON(R a R b), -C(=NH)-NH2, -C(=NH)-NHR a, -C(=NH)-N(R a R b), -C(=NR c)-NH2, -C(=NR c)-NHR a, -C(=NR c)-N(R aR b), -NH-C(=NH)-NH2, -NH-C(=NH)-NHR a, -NH-C(=NH)-N(R a R b), -NH-C(=NR c)-NH2, -NH-C(=NR c)-NHR a, -NH-C(=NR c)-N(R a R b), -NR d H-C(=NH)-NH2, -NR d-C(=NH)-NHR a, -NR d-C(=NH)-N(R
a R b), -NR d-C(=NR c)-NH2, -NR d-C(=NR c)-NHR a, -NR d-C(=NR c)-N(R aR'), -NHNH2, -NHNHR a, -NHR a R b, -SO2NH2, -SO2NHR a, -SO2NR a R b, -CH=CHR a, -CH=CR a R b, -CR
c=CR a R b,-CR c=CHR a, -CR c=CR a R b, -CCR a, -SH, -SR a, -S(O)R a, -S(O)2R a, alkyl group, non-aromatic heterocyclic group, benzyl group, or aryl group wherein R a-R d are each independently an alkyl group, benzyl, or aromatic group, or,-NR a R d, taken together, form a non-aromatic heterocyclic group.
a, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR a, -N(R a R b), -COOR a, -CHO, -CONH2, -CONHR a, -CON(R a R b), -NHCOR a, -NRCOR a, -NHCONH2, -NHCONR a H, -NHCON(R a R b), -NR c CONH2, -NR c CONR a H, -NR c CON(R a R b), -C(=NH)-NH2, -C(=NH)-NHR a, -C(=NH)-N(R a R b), -C(=NR c)-NH2, -C(=NR c)-NHR a, -C(=NR c)-N(R aR b), -NH-C(=NH)-NH2, -NH-C(=NH)-NHR a, -NH-C(=NH)-N(R a R b), -NH-C(=NR c)-NH2, -NH-C(=NR c)-NHR a, -NH-C(=NR c)-N(R a R b), -NR d H-C(=NH)-NH2, -NR d-C(=NH)-NHR a, -NR d-C(=NH)-N(R
a R b), -NR d-C(=NR c)-NH2, -NR d-C(=NR c)-NHR a, -NR d-C(=NR c)-N(R aR'), -NHNH2, -NHNHR a, -NHR a R b, -SO2NH2, -SO2NHR a, -SO2NR a R b, -CH=CHR a, -CH=CR a R b, -CR
c=CR a R b,-CR c=CHR a, -CR c=CR a R b, -CCR a, -SH, -SR a, -S(O)R a, -S(O)2R a, alkyl group, non-aromatic heterocyclic group, benzyl group, or aryl group wherein R a-R d are each independently an alkyl group, benzyl, or aromatic group, or,-NR a R d, taken together, form a non-aromatic heterocyclic group.
10. The compound of Claim 2 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y" is a covalent bond or -CH2.
or a pharmaceutically acceptable salt thereof wherein Y" is a covalent bond or -CH2.
11. The compound of Claim 10 wherein R5 and R6 are both a lower alkyl group or a phenyl group.
12. A compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein a) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
b) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 and R8 are both -H;
c) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
d) R1 and R2 are both 4-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
e) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
f) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 is methyl; R8 is -H;
g) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
h) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
i) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
j) R1 and R2 are both 3-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
k) R1 and R2 are both 3-fluorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
l) R1 and R2 are both 4-chlorophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
m) R1 and R2 are both 2-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
n) R1 and R2 are both 3-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
o) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
p) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
q) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
r) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
s) R1 and R2 are both 2,5-dichlorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H; and t) R1 and R2 are both 2,5-dimethylphenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
or a pharmaceutically acceptable salt thereof, wherein a) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
b) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 and R8 are both -H;
c) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
d) R1 and R2 are both 4-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
e) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
f) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 is methyl; R8 is -H;
g) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
h) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
i) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
j) R1 and R2 are both 3-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
k) R1 and R2 are both 3-fluorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
l) R1 and R2 are both 4-chlorophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
m) R1 and R2 are both 2-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
n) R1 and R2 are both 3-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
o) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
p) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
q) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
r) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
s) R1 and R2 are both 2,5-dichlorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H; and t) R1 and R2 are both 2,5-dimethylphenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group; and Z is =O or =S.
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group; and Z is =O or =S.
14. The pharmaceutical composition of Claim 13 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8- and R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8- and R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
15. The pharmaceutical composition of Claim 14 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8-.
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8-.
16. The pharmaceutical composition of Claim 15 wherein R1 and R2 are both phenyl or substituted phenyl; R3 and R4 are methyl, ethyl, phenyl, or thienyl; and R7 and R8 are both methyl; R7 and R8, taken together, are propylene or butylenes; or R7 is -H and R8 is lower alkyl, thienyl, phenyl or benzyl.
17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
18. The pharmaceutical composition of Claim 17 wherein R1 and R2 are both phenyl optionally substituted with one or more groups selected from -OH, -Br, -Cl, -I, -F, -OR
a, -O-COR a, -COR a, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR a, -N(R a R b), -COOR a, -CHO, -CONH2, -CONHR a, -CON(R a R b), -NHCOR a, -NRCOR a, -NHCONH2, -NHCONR a H, -NHCON(R a R b), -NR c CONH2, -NR c CONR a H, -NR c CON(R a R b), -C(=NH)-NH2, -C(=NH)-NHR a, -C(=NH)-N(R a R b), -C(=NR c)-NH2, -C(=NR c)-NHR a, -C(=NR c)-N(R a R
b), -NH-C(=NH)-NH2, -NH-C(=NH)-NHR a, -NH-C(=NH)-N(R a R b), -NH-C(=NR c)-NH2, -NH-C(=NR c)-NHR a, -NH-C(=NR c)-N(R a R b), -NR d H-C(=NH)-NH2, -NR d-C(=NH)-NHR
a, -NR d-C(=NH)-N(R a R b), -NR d-C(=NR c)-NH2, -NR d-C(=NR c)-NHR a, -NR d-C(=NR
c)-N(R a R b), -NHNH2, -NHNHR a, -NHR a R b, -SO2NH2, -SO2NHR a, -SO2NR a R b, -CH=CHR a, -CH=CR a R b, -CR c=CR a R b,-CR c=CHR a, -CR c=CR a R b, -CCR a, -SH, -SR a, -S(O)R a, -S(O)2R a, alkyl groups, non-aromatic heterocyclic group, benzyl group, or aryl group wherein R a-R d are each independently an alkyl group, benzyl, or aromatic group, or,-NR a R d, taken together, form a non-aromatic heterocyclic group.
a, -O-COR a, -COR a, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR a, -N(R a R b), -COOR a, -CHO, -CONH2, -CONHR a, -CON(R a R b), -NHCOR a, -NRCOR a, -NHCONH2, -NHCONR a H, -NHCON(R a R b), -NR c CONH2, -NR c CONR a H, -NR c CON(R a R b), -C(=NH)-NH2, -C(=NH)-NHR a, -C(=NH)-N(R a R b), -C(=NR c)-NH2, -C(=NR c)-NHR a, -C(=NR c)-N(R a R
b), -NH-C(=NH)-NH2, -NH-C(=NH)-NHR a, -NH-C(=NH)-N(R a R b), -NH-C(=NR c)-NH2, -NH-C(=NR c)-NHR a, -NH-C(=NR c)-N(R a R b), -NR d H-C(=NH)-NH2, -NR d-C(=NH)-NHR
a, -NR d-C(=NH)-N(R a R b), -NR d-C(=NR c)-NH2, -NR d-C(=NR c)-NHR a, -NR d-C(=NR
c)-N(R a R b), -NHNH2, -NHNHR a, -NHR a R b, -SO2NH2, -SO2NHR a, -SO2NR a R b, -CH=CHR a, -CH=CR a R b, -CR c=CR a R b,-CR c=CHR a, -CR c=CR a R b, -CCR a, -SH, -SR a, -S(O)R a, -S(O)2R a, alkyl groups, non-aromatic heterocyclic group, benzyl group, or aryl group wherein R a-R d are each independently an alkyl group, benzyl, or aromatic group, or,-NR a R d, taken together, form a non-aromatic heterocyclic group.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
a) R1 and R2 are both phenyl; R3 and R4 are both phenyl; R7 and R8 are both -H;
b) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 and R8 are both -H;
c) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
d) R1 and R2 are both 4-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
e) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
f) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 is methyl; R8 is -H;
g) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
h) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
i) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
j) R1 and R2 are both 3-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
k) R1 and R2 are both 3-fluorophenyl; R3 and R4are both methyl; R7 and R8 are both -H;
l) R1 and R2 are both 4-chlorophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
m) R1 and R2 are both 2-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
n) R1 and R2 are both 3-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
o) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
p) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
q) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
r) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
s) R1 and R2 are both 2,5-dichlorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
t) R1 and R2 are both 2,5-dimethylphenyl; R3 and R4 are both methyl; R7and R8 are both -H; and u) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7and R8 are both -H.
or a pharmaceutically acceptable salt thereof, wherein:
a) R1 and R2 are both phenyl; R3 and R4 are both phenyl; R7 and R8 are both -H;
b) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 and R8 are both -H;
c) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
d) R1 and R2 are both 4-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
e) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
f) R1 and R2 are both phenyl; R3 and R4 are both ethyl; R7 is methyl; R8 is -H;
g) R1 and R2 are both 4-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
h) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
i) R1 and R2 are both 2,5-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
j) R1 and R2 are both 3-cyanophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
k) R1 and R2 are both 3-fluorophenyl; R3 and R4are both methyl; R7 and R8 are both -H;
l) R1 and R2 are both 4-chlorophenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
m) R1 and R2 are both 2-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
n) R1 and R2 are both 3-methoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
o) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
p) R1 and R2 are both 2,3-dimethoxyphenyl; R3 and R4 are both methyl; R7 is methyl;
R8 is -H;
q) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
r) R1 and R2 are both 2,5-difluorophenyl; R3 and R4 are both methyl; R7 is methyl; R8 is -H;
s) R1 and R2 are both 2,5-dichlorophenyl; R3 and R4 are both methyl; R7 and R8 are both -H;
t) R1 and R2 are both 2,5-dimethylphenyl; R3 and R4 are both methyl; R7and R8 are both -H; and u) R1 and R2 are both phenyl; R3 and R4 are both methyl; R7and R8 are both -H.
20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
21. A use of an effective amount of a compound for enhancing an anti-cancer activity of paclitaxel or an analog thereof, wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, phenylene group or a substituted or unsubstituted hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R, and R2 are independently an aryl group or a substituted aryl group;
R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
and Z is =O or =S.
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, phenylene group or a substituted or unsubstituted hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R, and R2 are independently an aryl group or a substituted aryl group;
R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
and Z is =O or =S.
22. The use of Claim 21 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8- and R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond or -CR7R8- and R7 and R8 are each independently -H, an aliphatic or substituted aliphatic group, or R7 is -H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.
23. The use of Claim 22 wherein the paclitaxel analog is represented by a structural formula selected from:
wherein:
R10 is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group, -SR19, -NHR19 or -OR19;
R11 is a lower alkyl group, a substituted lower alkyl group, an aryl group or a substituted aryl group;
R12 is -H, -OH, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, -O-C(O)-(lower alkyl), -O-C(O)-(substituted lower alkyl), -O-CH2-O-(lower alkyl) -S-CH2-O-(lower alkyl);
R13 is -H, -CH3, or, taken together with R14, -CH2-;
R14 is -H, -OH, lower alkoxy, -O-C(O)-(lower alkyl), substituted lower alkoxy, -O-C(O)-(substituted lower alkyl), -O-CH2-O-P(O)(OH)2, -O-CH2-O-(lower alkyl), -O-CH2-S-(lower alkyl) or, taken together with R20, a double bond;
R15 -H, lower acyl, lower alkyl, substituted lower alkyl, alkoxymethyl, alkthiomethyl, -C(O)-O(lower alkyl), -C(O)-O(substituted lower alkyl), -C(O)-NH(lower alkyl) or -C(O)-NH(substituted lower alkyl);
R16 is phenyl or substituted phenyl;
R17 is -H, lower acyl, substituted lower acyl, lower alkyl, substituted, lower alkyl, (lower alkoxy)methyl or (lower alkyl)thiomethyl;
R18 -H, -CH3 or, taken together with R17 and the carbon atoms to which R17 and R18 are bonded, a five or six membered a non-aromatic heterocyclic ring;
R19 is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group;
R20 is -H or a halogen; and R21 is -H, lower alkyl, substituted lower alkyl, lower acyl or substituted lower acyl.
wherein:
R10 is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group, -SR19, -NHR19 or -OR19;
R11 is a lower alkyl group, a substituted lower alkyl group, an aryl group or a substituted aryl group;
R12 is -H, -OH, lower alkyl, substituted lower alkyl, lower alkoxy, substituted lower alkoxy, -O-C(O)-(lower alkyl), -O-C(O)-(substituted lower alkyl), -O-CH2-O-(lower alkyl) -S-CH2-O-(lower alkyl);
R13 is -H, -CH3, or, taken together with R14, -CH2-;
R14 is -H, -OH, lower alkoxy, -O-C(O)-(lower alkyl), substituted lower alkoxy, -O-C(O)-(substituted lower alkyl), -O-CH2-O-P(O)(OH)2, -O-CH2-O-(lower alkyl), -O-CH2-S-(lower alkyl) or, taken together with R20, a double bond;
R15 -H, lower acyl, lower alkyl, substituted lower alkyl, alkoxymethyl, alkthiomethyl, -C(O)-O(lower alkyl), -C(O)-O(substituted lower alkyl), -C(O)-NH(lower alkyl) or -C(O)-NH(substituted lower alkyl);
R16 is phenyl or substituted phenyl;
R17 is -H, lower acyl, substituted lower acyl, lower alkyl, substituted, lower alkyl, (lower alkoxy)methyl or (lower alkyl)thiomethyl;
R18 -H, -CH3 or, taken together with R17 and the carbon atoms to which R17 and R18 are bonded, a five or six membered a non-aromatic heterocyclic ring;
R19 is a lower alkyl group, a substituted lower alkyl group, a phenyl group, a substituted phenyl group;
R20 is -H or a halogen; and R21 is -H, lower alkyl, substituted lower alkyl, lower acyl or substituted lower acyl.
24. The use of Claim 23 wherein:
R10 is phenyl, tert-butoxy, -S-CH2-CH-(CH3)2, -S-CH(CH3)3, -S-(CH2)3CH3, -O-CH(CH3)3, -NH-CH(CH3)3, -CH=C(CH3)2 or para-chlorophenyl;
R11 is phenyl, (CH3)2CHCH2-, -2-furanyl, cyclopropyl or para-toluyl;
R12 is -H, -OH, CH3CO- or -(CH2)2-N-morpholino;
R13 is methyl, or, R13 and R14, taken together, are -CH2-;
R14 is -H, -CH2SCH3 or -CH2-O-P(O)(OH)2;
R15 is CH3CO-;
R16 is phenyl;
R17 -H, or, R17 and R18, taken together, are -O-CO-O-;
R18 is -H;
R20 is -H or -F; and R21 is -H, -C(O)-CHBr-(CH2)13-CH3 or -C(O)-(CH2)14-CH3; -C(O)-CH2-CH(OH)-COOH, -C(O)-CH2-O-C(O)-CH2CH(NH2)-CONH2, -C(O)-CH2-O-CH2CH2OCH3 or -C(O)-O-C(O)-CH2CH3.
R10 is phenyl, tert-butoxy, -S-CH2-CH-(CH3)2, -S-CH(CH3)3, -S-(CH2)3CH3, -O-CH(CH3)3, -NH-CH(CH3)3, -CH=C(CH3)2 or para-chlorophenyl;
R11 is phenyl, (CH3)2CHCH2-, -2-furanyl, cyclopropyl or para-toluyl;
R12 is -H, -OH, CH3CO- or -(CH2)2-N-morpholino;
R13 is methyl, or, R13 and R14, taken together, are -CH2-;
R14 is -H, -CH2SCH3 or -CH2-O-P(O)(OH)2;
R15 is CH3CO-;
R16 is phenyl;
R17 -H, or, R17 and R18, taken together, are -O-CO-O-;
R18 is -H;
R20 is -H or -F; and R21 is -H, -C(O)-CHBr-(CH2)13-CH3 or -C(O)-(CH2)14-CH3; -C(O)-CH2-CH(OH)-COOH, -C(O)-CH2-O-C(O)-CH2CH(NH2)-CONH2, -C(O)-CH2-O-CH2CH2OCH3 or -C(O)-O-C(O)-CH2CH3.
25. The use of Claim 22 wherein the paclitaxel analog is represented by a structure selected from the following structural formulas:
the paclitaxel analog is the copolymer of N-(2-hydroxypropyl)methacrylamide,methacryloylglycine-2-hydroxypropylamide and [2aR[2.alpha.,4.beta.,4.beta.,6.beta.,9.alpha.(2R,3S),11.beta.,12.alpha.,12.alp ha.,12.alpha.]]-6,12b-diacetoxy-9-[3-benzamido-2-(methacryloyl-glycyl-L-phenylalanyl-L-leucyl.glycyloxy)-3-phenylpropionyloxy]-benzoyloxy-4,11-dihydroxy-4a,8,13,13-tetramethyl-2a,3,4,4a,5,6,9,10,11,12,12a, 12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-5-one, or the paclitaxel analog is docetaxel.
the paclitaxel analog is the copolymer of N-(2-hydroxypropyl)methacrylamide,methacryloylglycine-2-hydroxypropylamide and [2aR[2.alpha.,4.beta.,4.beta.,6.beta.,9.alpha.(2R,3S),11.beta.,12.alpha.,12.alp ha.,12.alpha.]]-6,12b-diacetoxy-9-[3-benzamido-2-(methacryloyl-glycyl-L-phenylalanyl-L-leucyl.glycyloxy)-3-phenylpropionyloxy]-benzoyloxy-4,11-dihydroxy-4a,8,13,13-tetramethyl-2a,3,4,4a,5,6,9,10,11,12,12a, 12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-5-one, or the paclitaxel analog is docetaxel.
26. The use of Claim 23 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond.
or a pharmaceutically acceptable salt thereof wherein Y' is a covalent bond.
27. The use of Claim 23 wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof wherein Y' is -CR7R8-.
or a pharmaceutically acceptable salt thereof wherein Y' is -CR7R8-.
28. The use of Claim 27 wherein R1 and R2 are both aryl or substituted aryl groups and R3 and R4 are both a lower alkyl group or a substituted lower alkyl group.
29. A use of an effective amount of compound for enhancing the anti-cancer activity of paclitaxel or an analog thereof, wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
30. The use of Claim 29 wherein R, and R2 are both phenyl optionally substituted with one or more groups selected from -OH, -Br, -Cl, -I, -F, -OR a, -O-COR a, -COR a, -CN, -NO2, -COOH, -SO3H, -NH2, -NHR a, -N(R a R b), -COOR a, -CHO, -CONH2, -CONHR a, -CON(R a R b), -NHCOR a, -NRCOR a, -NHCONH2, -NHCONR a H, -NHCON(R a R b), -NR c CONH2, -NR c CONR a H, -NR c CON(R a R b), -C(=NH)-NH2, -C(=NH)-NHR a, -C(=NH)-N(R a R b), -C(=NR c)-NH2, -C(=NR c)-NHR a, -C(=NR c)-N(R a R b), -NH-C(=NH)-NH2, -NH-C(=NH)-NHR a, -NH-C(=NH)-N(R a R b), -NH-C(=NR c)-NH2, -NH-C(=NR c)-NHR a, -NH-C(=NR c)-N(R a R b), -NR d H-C(=NH)-NH2, -NR d-C(=NH)-NHR a, -NR d-C(=NH)-N(R
a R b), -NR d-C(=NR c)-NH2, -NR d-C(=NR c)-NHR a, -NR d-C(=NR c)-N(R a R b), -NHNH2, -NHNHR a, -NHR a R b, -SO2NH2, -SO2NHR a, -SO2NR a R b, -CH=CHR a, -CH=CR a R b, -CR c=CR a R b,-CR c=CHR a , -CR c=CR a R b, -CCR a, -SH, -SR a, -S(O)R a, -S(O)2R a, alkyl groups, non-aromatic heterocyclic group, benzyl group, or aryl group wherein R
a -R d are each independently an alkyl group, benzyl, or aromatic group, or,-NR a R d, taken together, form a non-aromatic heterocyclic group.
a R b), -NR d-C(=NR c)-NH2, -NR d-C(=NR c)-NHR a, -NR d-C(=NR c)-N(R a R b), -NHNH2, -NHNHR a, -NHR a R b, -SO2NH2, -SO2NHR a, -SO2NR a R b, -CH=CHR a, -CH=CR a R b, -CR c=CR a R b,-CR c=CHR a , -CR c=CR a R b, -CCR a, -SH, -SR a, -S(O)R a, -S(O)2R a, alkyl groups, non-aromatic heterocyclic group, benzyl group, or aryl group wherein R
a -R d are each independently an alkyl group, benzyl, or aromatic group, or,-NR a R d, taken together, form a non-aromatic heterocyclic group.
31. A use of an effective amount of a compound for enhancing the anti-cancer activity of paclitaxel, wherein the compound is represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
32. A use of an effective amount of a compound represented by the following structural formula, separately or together, with paclitaxel or a paclitaxel analog for simultaneous, sequential or separate administration in a treatment of cancer:
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, phenylene group or a substituted or unsubstituted hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R1 and R2 are independently an aryl group or a substituted aryl group;
R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
and Z is =O or =S.
or a pharmaceutically acceptable salt thereof, wherein:
Y is a covalent bond, phenylene group or a substituted or unsubstituted hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group;
R1 and R2 are independently an aryl group or a substituted aryl group;
R3 and R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
R5-R6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group;
and Z is =O or =S.
33. A use of an effective amount of a compound represented by the following structural formula, separately or together, with an effective amount of paclitaxel or a paclitaxel analog for simultaneous, sequential or separate administration in a treatment of cancer:
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
or a pharmaceutically acceptable salt thereof, wherein:
Y' is a covalent bond or -CR7R8-;
R1 and R2 are both a substituted or unsubstituted aryl group;
R3 and R4 are both -H, methyl or ethyl; and R7 is -H and R8 is -H or methyl.
34. A use of an effective amount of a compound represented by the following structural formula, separately or together, with an effective amount of paclitaxel or a paclitaxel analog for simultaneous, sequential or separate administration in a treatment of cancer:
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both phenyl; R3 and R4 are both methyl; R7 and R8 are both -H.
35. A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof.
36. The use of any of Claims 21-31 or 32-34, wherein the paclitaxel analog is docetaxel.
37. The use of any one of Claims 32-34, wherein the cancer is melanoma.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30425201P | 2001-07-10 | 2001-07-10 | |
| US60/304,252 | 2001-07-10 | ||
| US36194602P | 2002-03-06 | 2002-03-06 | |
| US60/361,946 | 2002-03-06 | ||
| PCT/US2002/021717 WO2003006430A1 (en) | 2001-07-10 | 2002-07-10 | Taxol enhancer compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2455453A1 CA2455453A1 (en) | 2003-01-23 |
| CA2455453C true CA2455453C (en) | 2011-02-15 |
Family
ID=26973915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2455453A Expired - Fee Related CA2455453C (en) | 2001-07-10 | 2002-07-10 | Taxol enhancer compounds |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US6800660B2 (en) |
| EP (3) | EP2289876A1 (en) |
| JP (1) | JP4344235B2 (en) |
| KR (2) | KR101060079B1 (en) |
| CN (1) | CN100348580C (en) |
| AT (2) | ATE533483T1 (en) |
| AU (1) | AU2002316626B2 (en) |
| BR (1) | BR0211227A (en) |
| CA (1) | CA2455453C (en) |
| CY (1) | CY1105811T1 (en) |
| DE (1) | DE60214718T2 (en) |
| DK (2) | DK1731148T3 (en) |
| ES (2) | ES2395193T3 (en) |
| HK (2) | HK1060115A1 (en) |
| IL (2) | IL159773A0 (en) |
| IS (1) | IS2412B (en) |
| MX (1) | MXPA04000244A (en) |
| NO (1) | NO329457B1 (en) |
| NZ (1) | NZ530963A (en) |
| PT (1) | PT1406869E (en) |
| SI (1) | SI1406869T1 (en) |
| TW (1) | TWI332943B (en) |
| WO (1) | WO2003006430A1 (en) |
| ZA (1) | ZA200401051B (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| US6924312B2 (en) * | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
| TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI330079B (en) * | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| AU2006228035B2 (en) * | 2003-01-15 | 2010-02-18 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer |
| KR101313027B1 (en) | 2004-06-23 | 2013-10-02 | 신타 파마슈티칼스 코프. | Bis(thio-hydrazide amide) salts for treatment of cancers |
| WO2006033913A2 (en) * | 2004-09-16 | 2006-03-30 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amides) for treament of hyperplasia |
| WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
| US8148426B2 (en) | 2004-11-19 | 2012-04-03 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amides) for increasing Hsp70 expression |
| JP2008536870A (en) * | 2005-04-15 | 2008-09-11 | シンタ ファーマシューティカルズ コーポレーション | Method for enhancing natural killer cell activity for treatment |
| NZ562572A (en) | 2005-04-15 | 2011-01-28 | Synta Pharmaceuticals Corp | Combination cancer therapy with BIS (thiohydrazide) amide compounds |
| KR20080008399A (en) | 2005-05-16 | 2008-01-23 | 신타 파마슈티칼스 코프. | Synthesis of bis(thio-hydrazide amide) salts |
| JP2009504740A (en) * | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | Bis (thio-hydrazide amide) formulation |
| TW200804307A (en) * | 2005-10-27 | 2008-01-16 | Synta Pharmaceuticals Corp | Process for preparing mesylate salts of IL-12 inhibitory compounds |
| WO2008024299A2 (en) * | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| CA2660524A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceutical Corp. | Compounds for treating proliferative disorders |
| EP2074097A2 (en) | 2006-08-21 | 2009-07-01 | Synta Pharmaceuticals Corporation | Compounds for treating proliferative disorders |
| JP2010501559A (en) * | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Bis (thiohydrazide amide) for use in preventing or delaying melanoma recurrence |
| EP2061451A2 (en) * | 2006-08-21 | 2009-05-27 | Synta Pharmaceuticals Corporation | Bis(thiohydrazide amides) for treating melanoma |
| CA2660531A1 (en) * | 2006-08-21 | 2008-02-28 | Synta Pharmaceutical Corp. | Compounds for treatment of proliferative disorders |
| AU2007290490B2 (en) | 2006-08-31 | 2011-09-08 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| TW200826926A (en) * | 2006-09-11 | 2008-07-01 | Synta Pharmaceuticals Corp | Bis (thiohydrazide amides) formulation |
| US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| US7645904B2 (en) * | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
| US20090093538A1 (en) * | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
| US8093425B2 (en) * | 2007-04-30 | 2012-01-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8729111B2 (en) | 2007-08-07 | 2014-05-20 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8618170B2 (en) * | 2007-11-09 | 2013-12-31 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
| WO2009073148A2 (en) * | 2007-11-28 | 2009-06-11 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
| TW200940050A (en) * | 2007-11-28 | 2009-10-01 | Synta Pharmaceuticals Corp | Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) |
| WO2009105257A1 (en) * | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2009123704A2 (en) * | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
| NZ592400A (en) | 2008-10-22 | 2013-09-27 | Synta Pharmaceuticals Corp | Transition metal complexes of bis[thiohydrazide amide] compounds |
| AU2009308511B2 (en) * | 2008-10-22 | 2013-03-07 | Synta Pharmaceutical Corp. | Transition metal complexes of a bis[thiohydrazide amide] compound |
| US8525776B2 (en) * | 2008-10-27 | 2013-09-03 | Lenovo (Singapore) Pte. Ltd | Techniques for controlling operation of a device with a virtual touchscreen |
| JP5631327B2 (en) | 2008-12-01 | 2014-11-26 | シンタ ファーマシューティカルズ コーポレーション | Compounds for treating proliferative disorders |
| WO2011069159A2 (en) | 2009-12-04 | 2011-06-09 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
| WO2011133673A1 (en) | 2010-04-20 | 2011-10-27 | Synta Pharmaceuticals Corp. | Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers |
| EP2776021A1 (en) | 2011-11-10 | 2014-09-17 | Synta Pharmaceuticals Corp. | Administration of a bis(thiohydrazide amide) compound for treating cancers |
| US20130149392A1 (en) * | 2011-12-12 | 2013-06-13 | Synta Pharmaceuticals Corp. | Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds |
| US20150057357A1 (en) | 2012-01-05 | 2015-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bis (thiohydrazide amide) compounds for treating cancers |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US304252A (en) | 1884-08-26 | Gael behee | ||
| US304318A (en) | 1884-09-02 | Inlet-pipe for water-works | ||
| US361946A (en) | 1887-04-26 | Watch arbor and pivot | ||
| US3357956A (en) * | 1965-03-30 | 1967-12-12 | Du Pont | Polymeric 1, 3, 4-thiadiazoles and the process for their preparation |
| FR2097737A5 (en) | 1970-07-14 | 1972-03-03 | Berlin Chemie Veb | Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4- |
| DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
| GB1272920A (en) | 1971-03-15 | 1972-05-03 | Berlin Chemie Veb | New thiosemicarbazides |
| US4012360A (en) * | 1973-12-03 | 1977-03-15 | Ciba-Geigy Corporation | Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines |
| JPS5091056A (en) * | 1973-12-17 | 1975-07-21 | ||
| US4822777A (en) | 1987-02-27 | 1989-04-18 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition |
| JP2767241B2 (en) | 1987-04-15 | 1998-06-18 | ロ−ム アンド ハ−ス コンパニ− | Pesticidal N- (optionally substituted) -N'-substituted-N, N'-disubstituted hydrazines |
| US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| DE69433723T3 (en) | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5840746A (en) | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
| US5523325A (en) | 1993-09-09 | 1996-06-04 | Jacobson; Richard M. | Amidrazones and their use as pesticides |
| BR9507914A (en) | 1994-06-03 | 1997-09-23 | Basf Ag | Carbamoil-carbo hydrazide Process for preparing carbamoyl-carbo-hydrazide Proper composition and process for controlling harmful fungi Use of carbamoyl-carbo-hydrazide and amino-acid-hydrazide |
| DE69604298T2 (en) | 1995-09-22 | 2000-05-18 | Bioimage A S Soeborg | VARIANTS OF THE GREEN FLUORESCENCE PROTEIN, GFP |
| US5739686A (en) | 1996-04-30 | 1998-04-14 | Naughton; Michael J. | Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection |
| KR980008219A (en) | 1996-07-16 | 1998-04-30 | 김상응 | Pharmaceutical composition for stabilized injection |
| JP2001523239A (en) * | 1997-04-18 | 2001-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Use of 5HT (3) antagonists to promote intestinal lavage |
| US6235787B1 (en) * | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
| GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| JP3099880B2 (en) * | 1998-08-12 | 2000-10-16 | 日本電気株式会社 | Semiconductor switch and switch circuit |
| TW479053B (en) | 1998-10-19 | 2002-03-11 | Agro Kanesho Co Ltd | Hydrazineoxoacetamide derivatives and pesticides |
| ES2161594B1 (en) * | 1998-12-17 | 2003-04-01 | Servier Lab | NEW DERIVATIVES OF HYDRAZIDE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| JP3908876B2 (en) * | 1999-07-23 | 2007-04-25 | 日東電工株式会社 | Base film for adhesive tape and adhesive tape or sheet |
| US6322303B1 (en) * | 2000-05-12 | 2001-11-27 | David M. John | Dunnage bag and method of making same |
| EP1164126A1 (en) | 2000-06-16 | 2001-12-19 | Basf Aktiengesellschaft | Salicylic acid hydrazide derivatives, process and intermediates for their preparation, agents containing them and their use for combatting damaging fungi |
| US6365745B1 (en) | 2000-07-14 | 2002-04-02 | Sumika Fine Chemicals Co., Ltd. | Method for producing hydrazine derivative |
| JP2004532187A (en) | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | Trisubstituted carbocyclic cyclophilin binding compounds and their uses |
| US20020198160A1 (en) | 2001-05-01 | 2002-12-26 | Everitt Elizabeth A. | Compositions and methods for enhancing the bioavailability of pharmaceutical agents |
| EP1387678A1 (en) | 2001-05-03 | 2004-02-11 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| US6602907B1 (en) * | 2001-06-08 | 2003-08-05 | University Of Central Florida | Treatment of breast cancer |
| TWI332943B (en) * | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| US6924312B2 (en) | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
| TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| ES2330927T3 (en) | 2001-11-28 | 2009-12-17 | Ipsen Pharma | DERIVATIVES OF 5-SULFANIL-4H-1,2,4-TRIAZOLS TO TREAT SOMATOSTATIN ASSOCIATED DISORDERS. |
| TW200408407A (en) | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| AU2006228035B2 (en) | 2003-01-15 | 2010-02-18 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| JP4921162B2 (en) | 2003-02-11 | 2012-04-25 | ヴァーナリス（ケンブリッジ）リミテッド | Isoxazole compounds as inhibitors of heat shock proteins |
| KR100575251B1 (en) | 2003-03-03 | 2006-05-02 | 재단법인서울대학교산학협력재단 | Pharmaceutical composition for treatment of cancer containing p38/JTV-1 as an effective component and screening method for pharmaceutical composition for treatment of cancer |
| EP1493445A1 (en) | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| KR100544347B1 (en) | 2003-12-11 | 2006-01-23 | 한국생명공학연구원 | Pharmaceutical compositions of diaryl-isoxazole compounds for the prevention and treatment of cancers |
| WO2005097758A1 (en) | 2004-03-26 | 2005-10-20 | Amphora Discovery Corporation | Certain triazole-based compounds, compositions, and uses thereof |
| KR101313027B1 (en) * | 2004-06-23 | 2013-10-02 | 신타 파마슈티칼스 코프. | Bis(thio-hydrazide amide) salts for treatment of cancers |
| US7385085B2 (en) * | 2004-07-09 | 2008-06-10 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| WO2006033913A2 (en) | 2004-09-16 | 2006-03-30 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amides) for treament of hyperplasia |
| US8148426B2 (en) | 2004-11-19 | 2012-04-03 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amides) for increasing Hsp70 expression |
| WO2006062732A2 (en) | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
| BRPI0607688A2 (en) | 2005-02-17 | 2009-09-22 | Synta Pharmaceuticals Corp | method for inhibiting tubulin polymerization in a cell; method for treating or preventing a proliferative disorder in an individual; method of blocking, occluding or otherwise disrupting blood flow to the neovasculature; compound; pharmaceutical composition and use of said method and compound |
| WO2006113493A2 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of determining cancer prognosis via natural killer cell activity |
| NZ562572A (en) * | 2005-04-15 | 2011-01-28 | Synta Pharmaceuticals Corp | Combination cancer therapy with BIS (thiohydrazide) amide compounds |
| JP2008536870A (en) | 2005-04-15 | 2008-09-11 | シンタ ファーマシューティカルズ コーポレーション | Method for enhancing natural killer cell activity for treatment |
| KR20080008399A (en) | 2005-05-16 | 2008-01-23 | 신타 파마슈티칼스 코프. | Synthesis of bis(thio-hydrazide amide) salts |
| JP2009504740A (en) | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | Bis (thio-hydrazide amide) formulation |
| US8318790B2 (en) | 2006-05-25 | 2012-11-27 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| EP2061451A2 (en) | 2006-08-21 | 2009-05-27 | Synta Pharmaceuticals Corporation | Bis(thiohydrazide amides) for treating melanoma |
| CA2660524A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceutical Corp. | Compounds for treating proliferative disorders |
| EP2074097A2 (en) | 2006-08-21 | 2009-07-01 | Synta Pharmaceuticals Corporation | Compounds for treating proliferative disorders |
| JP2010501559A (en) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Bis (thiohydrazide amide) for use in preventing or delaying melanoma recurrence |
| WO2008024298A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Bis(thiohydrazide amides) for inhibiting angiogenesis |
| WO2008024299A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| AU2007290490B2 (en) | 2006-08-31 | 2011-09-08 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| TW200826926A (en) | 2006-09-11 | 2008-07-01 | Synta Pharmaceuticals Corp | Bis (thiohydrazide amides) formulation |
| AU2007294752A1 (en) | 2006-09-14 | 2008-03-20 | Synta Pharmaceuticals Corp. | Compounds for the treatment of angiogenesis |
| US7645904B2 (en) | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
| US20090093538A1 (en) | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
| US8093425B2 (en) | 2007-04-30 | 2012-01-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8729111B2 (en) | 2007-08-07 | 2014-05-20 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8618170B2 (en) | 2007-11-09 | 2013-12-31 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
| TW200940050A (en) | 2007-11-28 | 2009-10-01 | Synta Pharmaceuticals Corp | Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) |
| WO2009073148A2 (en) | 2007-11-28 | 2009-06-11 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
-
2002
- 2002-07-09 TW TW091115207A patent/TWI332943B/en not_active IP Right Cessation
- 2002-07-10 KR KR1020107011643A patent/KR101060079B1/en not_active IP Right Cessation
- 2002-07-10 ES ES06019066T patent/ES2395193T3/en not_active Expired - Lifetime
- 2002-07-10 BR BR0211227-2A patent/BR0211227A/en not_active IP Right Cessation
- 2002-07-10 CA CA2455453A patent/CA2455453C/en not_active Expired - Fee Related
- 2002-07-10 ES ES02746947T patent/ES2271292T3/en not_active Expired - Lifetime
- 2002-07-10 DK DK06019066.7T patent/DK1731148T3/en active
- 2002-07-10 AU AU2002316626A patent/AU2002316626B2/en not_active Ceased
- 2002-07-10 EP EP10075453A patent/EP2289876A1/en not_active Withdrawn
- 2002-07-10 NZ NZ530963A patent/NZ530963A/en not_active IP Right Cessation
- 2002-07-10 EP EP02746947A patent/EP1406869B1/en not_active Expired - Lifetime
- 2002-07-10 DK DK02746947T patent/DK1406869T3/en active
- 2002-07-10 CN CNB028177339A patent/CN100348580C/en not_active Expired - Fee Related
- 2002-07-10 WO PCT/US2002/021717 patent/WO2003006430A1/en active Application Filing
- 2002-07-10 JP JP2003512202A patent/JP4344235B2/en not_active Expired - Fee Related
- 2002-07-10 EP EP06019066A patent/EP1731148B1/en not_active Expired - Lifetime
- 2002-07-10 DE DE60214718T patent/DE60214718T2/en not_active Expired - Lifetime
- 2002-07-10 MX MXPA04000244A patent/MXPA04000244A/en active IP Right Grant
- 2002-07-10 SI SI200230432T patent/SI1406869T1/en unknown
- 2002-07-10 PT PT02746947T patent/PT1406869E/en unknown
- 2002-07-10 AT AT06019066T patent/ATE533483T1/en active
- 2002-07-10 IL IL15977302A patent/IL159773A0/en unknown
- 2002-07-10 KR KR1020047000358A patent/KR100990581B1/en active IP Right Grant
- 2002-07-10 AT AT02746947T patent/ATE339402T1/en active
- 2002-07-10 US US10/193,075 patent/US6800660B2/en not_active Expired - Fee Related
-
2004
- 2004-01-08 IL IL159773A patent/IL159773A/en not_active IP Right Cessation
- 2004-01-09 IS IS7101A patent/IS2412B/en unknown
- 2004-01-09 NO NO20040095A patent/NO329457B1/en not_active IP Right Cessation
- 2004-02-09 ZA ZA2004/01051A patent/ZA200401051B/en unknown
- 2004-04-29 HK HK04103011A patent/HK1060115A1/en not_active IP Right Cessation
- 2004-05-14 US US10/846,152 patent/US7037940B2/en not_active Expired - Fee Related
-
2005
- 2005-10-05 US US11/244,324 patent/US7345094B2/en not_active Expired - Fee Related
-
2006
- 2006-11-29 CY CY20061101719T patent/CY1105811T1/en unknown
-
2007
- 2007-06-12 HK HK07106258.7A patent/HK1101543A1/en not_active IP Right Cessation
-
2008
- 2008-01-18 US US12/009,641 patent/US7671092B2/en not_active Expired - Fee Related
-
2010
- 2010-01-25 US US12/692,895 patent/US9107955B2/en not_active Expired - Fee Related
-
2015
- 2015-08-14 US US14/826,889 patent/US20150344420A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2455453C (en) | Taxol enhancer compounds | |
| CA2454120C (en) | Taxol enhancer compounds | |
| US6924312B2 (en) | Taxol enhancer compounds | |
| AU2002316626A1 (en) | Taxol enhancer compounds | |
| AU2002354641A1 (en) | Taxol enhancer compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170710 |